CA2361646A1 - An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system - Google Patents
An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system Download PDFInfo
- Publication number
- CA2361646A1 CA2361646A1 CA002361646A CA2361646A CA2361646A1 CA 2361646 A1 CA2361646 A1 CA 2361646A1 CA 002361646 A CA002361646 A CA 002361646A CA 2361646 A CA2361646 A CA 2361646A CA 2361646 A1 CA2361646 A1 CA 2361646A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- human
- domain
- inhibitory activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001413 cellular effect Effects 0.000 title claims abstract description 16
- 230000006870 function Effects 0.000 title abstract description 23
- 210000000987 immune system Anatomy 0.000 title abstract description 11
- 239000012636 effector Substances 0.000 title abstract description 10
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 44
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 44
- 239000013598 vector Substances 0.000 claims abstract description 40
- 108020004414 DNA Proteins 0.000 claims abstract description 30
- 230000009261 transgenic effect Effects 0.000 claims abstract description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 21
- 210000000056 organ Anatomy 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 126
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 claims description 66
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 64
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 54
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 50
- 230000002401 inhibitory effect Effects 0.000 claims description 48
- 102100022002 CD59 glycoprotein Human genes 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 claims description 20
- 230000001177 retroviral effect Effects 0.000 claims description 17
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 108091006086 inhibitor proteins Proteins 0.000 claims description 8
- 230000024932 T cell mediated immunity Effects 0.000 claims description 6
- 239000013599 cloning vector Substances 0.000 claims description 4
- 101000935814 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) Periplasmic beta-glucosidase Proteins 0.000 claims description 2
- 230000028996 humoral immune response Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 14
- 230000001105 regulatory effect Effects 0.000 abstract description 11
- 238000010367 cloning Methods 0.000 abstract description 9
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 description 39
- 238000000034 method Methods 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 35
- 150000001413 amino acids Chemical group 0.000 description 32
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 24
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 21
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 21
- 238000002054 transplantation Methods 0.000 description 21
- 102000051442 human CD59 Human genes 0.000 description 20
- 239000012634 fragment Substances 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 16
- 210000000612 antigen-presenting cell Anatomy 0.000 description 16
- 102000000588 Interleukin-2 Human genes 0.000 description 15
- 108010002350 Interleukin-2 Proteins 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 15
- 241000282898 Sus scrofa Species 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 13
- 102000043321 human CTLA4 Human genes 0.000 description 13
- 230000006044 T cell activation Effects 0.000 description 12
- 239000012091 fetal bovine serum Substances 0.000 description 12
- 238000003752 polymerase chain reaction Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 238000002689 xenotransplantation Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 229940098773 bovine serum albumin Drugs 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000004806 packaging method and process Methods 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 238000003556 assay Methods 0.000 description 10
- 230000000139 costimulatory effect Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 108010009575 CD55 Antigens Proteins 0.000 description 9
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 9
- 230000000747 cardiac effect Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 238000010369 molecular cloning Methods 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 8
- 102000050019 Membrane Cofactor Human genes 0.000 description 8
- 101710146216 Membrane cofactor protein Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 210000001671 embryonic stem cell Anatomy 0.000 description 8
- 210000002257 embryonic structure Anatomy 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 7
- 239000012981 Hank's balanced salt solution Substances 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 229940124073 Complement inhibitor Drugs 0.000 description 6
- 108700019146 Transgenes Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000004074 complement inhibitor Substances 0.000 description 6
- 230000004940 costimulation Effects 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 108010047620 Phytohemagglutinins Proteins 0.000 description 5
- 241000288906 Primates Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 210000002403 aortic endothelial cell Anatomy 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000006037 cell lysis Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 238000000520 microinjection Methods 0.000 description 5
- 230000001885 phytohemagglutinin Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 208000001608 teratocarcinoma Diseases 0.000 description 5
- 208000009329 Graft vs Host Disease Diseases 0.000 description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 230000004154 complement system Effects 0.000 description 4
- 210000003038 endothelium Anatomy 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 208000024908 graft versus host disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229960002378 oftasceine Drugs 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000139306 Platt Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 102000014384 Type C Phospholipases Human genes 0.000 description 3
- 108010079194 Type C Phospholipases Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000014107 chromosome localization Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 102000034356 gene-regulatory proteins Human genes 0.000 description 3
- 108091006104 gene-regulatory proteins Proteins 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000004073 interleukin-2 production Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229950010131 puromycin Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 108010045634 B7 Antigens Proteins 0.000 description 2
- 102000005738 B7 Antigens Human genes 0.000 description 2
- 108010035053 B7-1 Antigen Proteins 0.000 description 2
- 102000038504 B7-1 Antigen Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000001324 CD59 Antigens Human genes 0.000 description 2
- 108010055167 CD59 Antigens Proteins 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 102000016550 Complement Factor H Human genes 0.000 description 2
- 108010053085 Complement Factor H Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000701062 Saimiriine gammaherpesvirus 2 Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 1
- 235000005749 Anthriscus sylvestris Nutrition 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000016574 Complement C3-C5 Convertases Human genes 0.000 description 1
- 108010067641 Complement C3-C5 Convertases Proteins 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006471 Fucosyltransferases Human genes 0.000 description 1
- 108010019236 Fucosyltransferases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000219726 Griffonia simplicifolia Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000028523 Hereditary Complement Deficiency disease Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000700195 Hydrochoerus hydrochaeris Species 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100039373 Membrane cofactor protein Human genes 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 241001212279 Neisseriales Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 101000911993 Ovis aries CD59 glycoprotein Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 102000013803 T cell antigen CD28 Human genes 0.000 description 1
- 108050003635 T cell antigen CD28 Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000287433 Turdus Species 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000002388 complement deficiency Diseases 0.000 description 1
- 102000006834 complement receptors Human genes 0.000 description 1
- 108010047295 complement receptors Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 102000044446 human CD46 Human genes 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016788 immune system process Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 238000010449 nuclear transplantation Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000012250 transgenic expression Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011131 xenogeneic cell therapy Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Recombinant chimeric molecules that include at least a domain capable of regulating the humoral effector functions of the immune system and another domain capable of regulating the cellular effector functions of the immune system are provided. Recombinant DNA constructs having DNA sequences encoding the above mentioned chimeric proteins are provided. Cloning vectors incorporating the above DNA constructs and cells transformed with the vectors and host cells containing such vectors are also provided. Transgenic cells, tissues, organs, and animals incorporating the above-mentioned chimeric molecules are provided.
Description
AN ENGINEERED RECOMBINANT MOLECULE THAT REGULATES
HUMORAL AND CELLULAR EFFECTOR FUNCTIONS OF THE IyIMUNE
SYSTEM
Technical Field Chimeric proteins capable of confering resistance to humoral and cellular mechanisms of immune attack and more particularly chimeric proteins having at least a domain derived from a complement inhibitor protein and a domain derived from a T-Cell inhibitor protein are provided.
DNA constructs encoding such chimeric proteins and methods of preparing such chimeric proteins are disclosed. Methods of using such chimeric proteins, including in the prevention or treatment of rejection of xenotransplants are described.
Background Chimeric proteins, also referred to in the art as fusion proteins, are hybrid proteins which combine at least parts of two or more precursor proteins or peptides. Chimeric proteins may be produced by recombinant technology, i.e. by fusing at least a part of the coding sequence of one gene to at least a part of the coding sequence of another gene. The fused gene may then be used to transform a suitable organism which then expresses the fusion protein.
It is known in the art that T cells, also called T lymphocytes, are a part of the vertebrate immune system. T cells recognize foreign pathogens (such as bacteria, viruses, or parasites), tissues, and or organs, and help the immune system process them (causing what is referred to in the art as a cellular immune response), generally clearing the pathogens from the bodv. T cell activation is not only dependent on antigen recognition, but also on engagement of costimulatory molecules found on antigen presenting cells (APCs). The costimulatory signal that determines whether antigen recognition leads to full T cell activation or to T cell unresponsiveness, i.e.
anergy, is that generated by the interaction of CD28 on the T cells with B7 on the APCs; see for example Harding et al., Nature (1992) 356:607 who demonstrated in vitro that cross-linking of the CD28 molecule can rescue T cells from becoming anergic. It is further known that both B7-1 (CD80) and B7-2 (CD86) molecules on APCs provide critical costimulatory signals in T cell activation through their binding with the CD28 molecule on the T cell, and, moreover, that antigens presented in the absence of such costimulatory signals results in T cell anergy.
It is also known in the art that the complement system, (known in the art to be part of the humoral immune system) is an interaction of at least 25 plasma proteins and membrane cofactors which act in a multistep, multiprotein cascade sequence in conjunction with other immunological WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 systems of the body t~ _~fend against intrusion of foreign cells and vir~ .,s.
Complement components achieve their immune defensive functions by interacting in a series of intricate but precise enzymatic cleavage and membrane binding events. The resulting complement cascade leads to the production of products with opsonic, immunoregulatory, and lytic functions.
CD59 is known to be the archetypical inhibitor of part of the complement system known as the C5b-9 membrane attack complex (MAC). When activated and not inhibited the C5b-9 MAC
can cause potentially deleterious cell activation including cell lysis. CD59 is a human glycoprotein, the nucleotide and amino acid sequences for which are set forth in Figure 2E1.
CD59 is found associated with the membranes of cells including human erythrocytes, lymphocytes, and vascular endothelial cells. It serves to prevent assembly of functional MACs and thus protects cells from complement-mediated activation and/or lysis and is tethered to the outside of the cell membrane by a glycosyl-phosphatidylinositol (GPI) anchor. See, for example, Sims et al., U.S. Pat. No.
5,135,916.
Both humoral and cellular defense mechanisms mediate the rejection of transplanted cells, tissues, and organs during xenotransplantation. The survival of organs and tissues during xenotransplantation requires multiple immunosuppressive strategies to inhibit antibody reactivity, complement activation, and cellular rejection.
Bi-functional complement inhibitor s including fusion proteins constructed from the C3 family of inhibitor proteins (such DAF or CD55) and the CSb-9 family of inhibitor proteins (such as CD59) are known. See U.S. Patents 5,847,082, 5,624,837, and 5,627,264. It has been demonstrated that the CD59 moiety in a DAF-CD59 chimeric molecule functions to inhibit MAC
when expressed membrane proximal and anchored through its endogenous GPI
linkage. See Fodor et al., (J. Immunol., 155:4135, 1995).
Various techniques have been investigated to regulate T-cell interactions and immune responses mediated by such interactions. It is known that CTLA4 is a T-cell surface receptor that associates with the B7-1 (CD80) and B7-2 (CD86) molecules which are expressed on antigen-presenting cells. See for example Hancock et al. "Comparative Analysis of B7-1 and B7-2 Co-Stimulatory Ligands: Expression and Function" J. Exp. Med., 180:631, 1994. It is further known that this association establishes the molecular basis for an important T
Cell co-stimulatory pathway, the primary function of which is to induce T-cell cytokine production and proliferation following exposure to antigen. See for example Linsley et al., J. Exp. Med.
173:721-730,1991.
U.S. Patent 5,434,131 identifies the CTLA4 receptor as a ligand for the B7 antigen and discloses methods for using soluble fusion proteins to regulate immune responses, including T-cell interactions. U.S. Patent 5,773,253 provides CTLA4 mutant molecules as ligands for the B7 antigen and methods for expressing the mutant molecules as soluble functional molecules which regulate T-cell interactions. U.S. Patents 5,844,095 and 5,851,795 describe methods of expressing CTLA4 as an immunoglobulin fusion protein, methods of preparing hybrid CTLA4 WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 fusion proteins, and memods of using the soluble fusion proteins, fragm.;uts and derivatives thereof, to regulate cellular immune responses and T-cell interactions. U.S
Patent x,869,050 discloses methods of blocking T-cell activation using anti-B7 monoclonal antibodies to overcome allograft transplant rejection and/or graft versus host disease, as well as to prevent or treat rheumatoid arthritis.
However, no single molecule exists today which can be used in the prevention or treatment of both humoral and cellular rejection of xenotransplants. No such molecules exist that when expressed provide the cell with both protection from human serum complement and inhibit T-cell activation. Such a molecule would be particularly advantageous in the production of transgenic animals. Microinjection of recombinant DNA into the pronuclei of animal ova for generating transgenic animals is known. However, since this technology is dependent on random integration of DNA, it is a complex procedure to achieve targeted cellular expression of two distinct heterologous proteins by the simultaneous microinjection of their respective DNAs (such as would be required if CTLA4 inhibitory activity and CD59 inhibitory activity were to be achieved through the use of individual entities.) Moreover, as described above, currently the soluble form of CTLA4 or CTLA4IG
fusion proteins are used to regulate cellular immune responses and T-cell interactions. Therefore, it would be of additional advantage if the CTLA4 moiety could bind endogenously expressed B7-1 and B7-2 molecules in cis and block the co-stimulation necessary for engagement of human CD28 expressed on T-cells, thereby protecting the xenotransplanted porcine cell from the human cellular immune response by rendering the human T-cells unresponsive to the porcine target cell.
Summary Recombinant chimeric molecules that include at least a domain capable of regulating the humoral effector functions of the immune system and another domain capable of regulating the cellular effector functions of the immune system now surprisingly have been engineered. Suitable domains capable of regulating the humoral effector functions of the immune system include complement inhibitory domains, such as a CSb-9 and/or C3 inhibitory domains.
Suitable domains capable of regulating the cellular effector functions of the immune system include T Cell inhibitory domains. In one embodiment, a membrane bound chimeric molecule which includes functional domains derived from CTLA4 and CD59 is provided. In another embodiment, a membrane bound chimeric molecule which includes functional domains derived from CTLA4 and DAF is provided.
Recombinant DNA constructs having DNA sequences encoding the above mentioned chimeric proteins are provided. Cloning vectors incorporating the above DNA
constructs and cells transformed with the vectors and host cells containing such vectors are also provided. Transgenic WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 cells, tissues, organs, anu animals incorporating the above-mentioned ch..neric molecules are provided.
Methods for preparing a DNA construct including a DNA sequence encoding a CD59 inhibitory domain operably linked to a DNA sequence encoding a T Cell inhibitory domain are provided. Also provided are methods of manufacturing the above described chimeric proteins by transforming a cell with a suitable cloning vector including a DNA construct encoding the chimeric protein, and expressing the gene such that the resulting protein on the cell membrane.
Brief Description Of The Drawings Fig. 1 depicts a diagramatic representation of the recombinant chimeric molecules.
Fig. 2A( 1 ) depicts the DNA used in the cloning of porcine CTLA4 - human CD59 chimeric molecules.
Fig. 2A(2) depicts the amino acid sequence of porcine CTLA4 - human CD59 chimeric molecules.
Fig. 2B(1) depicts the DNA used in the cloning of human CTLA4 - human CD59 chimeric molecules.
Fig. 2B(2) depicts the amino acid sequence of human CTLA4 - human CD59 chimeric molecules.
Fig. 2C ( 1 ) depicts the DNA sequence of porcine CTLA4.
Fig. 2C(2) depicts the amino acid sequence of porcine CTLA4.
Fig. 2D( 1 ) depicts the DNA sequence of human CTLA4.
Fig. 2D(2) depicts the amino acid sequence of human CTLA4.
Fig. 2E ( 1 ) depicts the DNA sequence of human CD59.
Fig. 2E(2) depicts the amino acid sequence of human CD59.
Fig. 3 are florescence activated cell sorting (FACS) profiles that demonstrate the expression of the CTLA4 and CD59 domains of the chimeric molecules on the cell surface of transduced PAECs. Cell surface expression of hCC. Drug resistent populations of porcine aortic endothelial cells (PAECs) transduced with pBABEhCTLA4-hCD59 or pBABE vector alone were assayed for expression of CD59 and CTLA4. Briefly, cells were incubated with l0ug/ml anti CTLA4, ANC152.2 (Ancell, Bayport, MN) or with l0ug/ml of either of the anti-CD59 antibodies, BRAlOG or MEM43 (Biodesign, Kennebunk, ME) , for 30 min., at 4C, in 0.1 m 1 of Dulbecco's PBS (DPBS) containing 1% Fetal Bovine Serum (FBS) or Bovine Serum Albumin (BSA). Cells were washed with DPBS before incubation with FITC conjugated antibodies to mouse IgG (Zymed, So.San Francisco, CA).
Cells were analysed on a Becton Dickenson FACSORT (Becton Dickenson, Franklin Lakes, NJ). Phosphatidyl inositol phospholipase C (PI-PLC) enzymatically cleaves gpi-linked molecules from the surface of cells and therefore should cleave the hCTLA4-hCD59 and pCTLA4-hCD59 molecules from the transduced PAECs.
HUMORAL AND CELLULAR EFFECTOR FUNCTIONS OF THE IyIMUNE
SYSTEM
Technical Field Chimeric proteins capable of confering resistance to humoral and cellular mechanisms of immune attack and more particularly chimeric proteins having at least a domain derived from a complement inhibitor protein and a domain derived from a T-Cell inhibitor protein are provided.
DNA constructs encoding such chimeric proteins and methods of preparing such chimeric proteins are disclosed. Methods of using such chimeric proteins, including in the prevention or treatment of rejection of xenotransplants are described.
Background Chimeric proteins, also referred to in the art as fusion proteins, are hybrid proteins which combine at least parts of two or more precursor proteins or peptides. Chimeric proteins may be produced by recombinant technology, i.e. by fusing at least a part of the coding sequence of one gene to at least a part of the coding sequence of another gene. The fused gene may then be used to transform a suitable organism which then expresses the fusion protein.
It is known in the art that T cells, also called T lymphocytes, are a part of the vertebrate immune system. T cells recognize foreign pathogens (such as bacteria, viruses, or parasites), tissues, and or organs, and help the immune system process them (causing what is referred to in the art as a cellular immune response), generally clearing the pathogens from the bodv. T cell activation is not only dependent on antigen recognition, but also on engagement of costimulatory molecules found on antigen presenting cells (APCs). The costimulatory signal that determines whether antigen recognition leads to full T cell activation or to T cell unresponsiveness, i.e.
anergy, is that generated by the interaction of CD28 on the T cells with B7 on the APCs; see for example Harding et al., Nature (1992) 356:607 who demonstrated in vitro that cross-linking of the CD28 molecule can rescue T cells from becoming anergic. It is further known that both B7-1 (CD80) and B7-2 (CD86) molecules on APCs provide critical costimulatory signals in T cell activation through their binding with the CD28 molecule on the T cell, and, moreover, that antigens presented in the absence of such costimulatory signals results in T cell anergy.
It is also known in the art that the complement system, (known in the art to be part of the humoral immune system) is an interaction of at least 25 plasma proteins and membrane cofactors which act in a multistep, multiprotein cascade sequence in conjunction with other immunological WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 systems of the body t~ _~fend against intrusion of foreign cells and vir~ .,s.
Complement components achieve their immune defensive functions by interacting in a series of intricate but precise enzymatic cleavage and membrane binding events. The resulting complement cascade leads to the production of products with opsonic, immunoregulatory, and lytic functions.
CD59 is known to be the archetypical inhibitor of part of the complement system known as the C5b-9 membrane attack complex (MAC). When activated and not inhibited the C5b-9 MAC
can cause potentially deleterious cell activation including cell lysis. CD59 is a human glycoprotein, the nucleotide and amino acid sequences for which are set forth in Figure 2E1.
CD59 is found associated with the membranes of cells including human erythrocytes, lymphocytes, and vascular endothelial cells. It serves to prevent assembly of functional MACs and thus protects cells from complement-mediated activation and/or lysis and is tethered to the outside of the cell membrane by a glycosyl-phosphatidylinositol (GPI) anchor. See, for example, Sims et al., U.S. Pat. No.
5,135,916.
Both humoral and cellular defense mechanisms mediate the rejection of transplanted cells, tissues, and organs during xenotransplantation. The survival of organs and tissues during xenotransplantation requires multiple immunosuppressive strategies to inhibit antibody reactivity, complement activation, and cellular rejection.
Bi-functional complement inhibitor s including fusion proteins constructed from the C3 family of inhibitor proteins (such DAF or CD55) and the CSb-9 family of inhibitor proteins (such as CD59) are known. See U.S. Patents 5,847,082, 5,624,837, and 5,627,264. It has been demonstrated that the CD59 moiety in a DAF-CD59 chimeric molecule functions to inhibit MAC
when expressed membrane proximal and anchored through its endogenous GPI
linkage. See Fodor et al., (J. Immunol., 155:4135, 1995).
Various techniques have been investigated to regulate T-cell interactions and immune responses mediated by such interactions. It is known that CTLA4 is a T-cell surface receptor that associates with the B7-1 (CD80) and B7-2 (CD86) molecules which are expressed on antigen-presenting cells. See for example Hancock et al. "Comparative Analysis of B7-1 and B7-2 Co-Stimulatory Ligands: Expression and Function" J. Exp. Med., 180:631, 1994. It is further known that this association establishes the molecular basis for an important T
Cell co-stimulatory pathway, the primary function of which is to induce T-cell cytokine production and proliferation following exposure to antigen. See for example Linsley et al., J. Exp. Med.
173:721-730,1991.
U.S. Patent 5,434,131 identifies the CTLA4 receptor as a ligand for the B7 antigen and discloses methods for using soluble fusion proteins to regulate immune responses, including T-cell interactions. U.S. Patent 5,773,253 provides CTLA4 mutant molecules as ligands for the B7 antigen and methods for expressing the mutant molecules as soluble functional molecules which regulate T-cell interactions. U.S. Patents 5,844,095 and 5,851,795 describe methods of expressing CTLA4 as an immunoglobulin fusion protein, methods of preparing hybrid CTLA4 WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 fusion proteins, and memods of using the soluble fusion proteins, fragm.;uts and derivatives thereof, to regulate cellular immune responses and T-cell interactions. U.S
Patent x,869,050 discloses methods of blocking T-cell activation using anti-B7 monoclonal antibodies to overcome allograft transplant rejection and/or graft versus host disease, as well as to prevent or treat rheumatoid arthritis.
However, no single molecule exists today which can be used in the prevention or treatment of both humoral and cellular rejection of xenotransplants. No such molecules exist that when expressed provide the cell with both protection from human serum complement and inhibit T-cell activation. Such a molecule would be particularly advantageous in the production of transgenic animals. Microinjection of recombinant DNA into the pronuclei of animal ova for generating transgenic animals is known. However, since this technology is dependent on random integration of DNA, it is a complex procedure to achieve targeted cellular expression of two distinct heterologous proteins by the simultaneous microinjection of their respective DNAs (such as would be required if CTLA4 inhibitory activity and CD59 inhibitory activity were to be achieved through the use of individual entities.) Moreover, as described above, currently the soluble form of CTLA4 or CTLA4IG
fusion proteins are used to regulate cellular immune responses and T-cell interactions. Therefore, it would be of additional advantage if the CTLA4 moiety could bind endogenously expressed B7-1 and B7-2 molecules in cis and block the co-stimulation necessary for engagement of human CD28 expressed on T-cells, thereby protecting the xenotransplanted porcine cell from the human cellular immune response by rendering the human T-cells unresponsive to the porcine target cell.
Summary Recombinant chimeric molecules that include at least a domain capable of regulating the humoral effector functions of the immune system and another domain capable of regulating the cellular effector functions of the immune system now surprisingly have been engineered. Suitable domains capable of regulating the humoral effector functions of the immune system include complement inhibitory domains, such as a CSb-9 and/or C3 inhibitory domains.
Suitable domains capable of regulating the cellular effector functions of the immune system include T Cell inhibitory domains. In one embodiment, a membrane bound chimeric molecule which includes functional domains derived from CTLA4 and CD59 is provided. In another embodiment, a membrane bound chimeric molecule which includes functional domains derived from CTLA4 and DAF is provided.
Recombinant DNA constructs having DNA sequences encoding the above mentioned chimeric proteins are provided. Cloning vectors incorporating the above DNA
constructs and cells transformed with the vectors and host cells containing such vectors are also provided. Transgenic WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 cells, tissues, organs, anu animals incorporating the above-mentioned ch..neric molecules are provided.
Methods for preparing a DNA construct including a DNA sequence encoding a CD59 inhibitory domain operably linked to a DNA sequence encoding a T Cell inhibitory domain are provided. Also provided are methods of manufacturing the above described chimeric proteins by transforming a cell with a suitable cloning vector including a DNA construct encoding the chimeric protein, and expressing the gene such that the resulting protein on the cell membrane.
Brief Description Of The Drawings Fig. 1 depicts a diagramatic representation of the recombinant chimeric molecules.
Fig. 2A( 1 ) depicts the DNA used in the cloning of porcine CTLA4 - human CD59 chimeric molecules.
Fig. 2A(2) depicts the amino acid sequence of porcine CTLA4 - human CD59 chimeric molecules.
Fig. 2B(1) depicts the DNA used in the cloning of human CTLA4 - human CD59 chimeric molecules.
Fig. 2B(2) depicts the amino acid sequence of human CTLA4 - human CD59 chimeric molecules.
Fig. 2C ( 1 ) depicts the DNA sequence of porcine CTLA4.
Fig. 2C(2) depicts the amino acid sequence of porcine CTLA4.
Fig. 2D( 1 ) depicts the DNA sequence of human CTLA4.
Fig. 2D(2) depicts the amino acid sequence of human CTLA4.
Fig. 2E ( 1 ) depicts the DNA sequence of human CD59.
Fig. 2E(2) depicts the amino acid sequence of human CD59.
Fig. 3 are florescence activated cell sorting (FACS) profiles that demonstrate the expression of the CTLA4 and CD59 domains of the chimeric molecules on the cell surface of transduced PAECs. Cell surface expression of hCC. Drug resistent populations of porcine aortic endothelial cells (PAECs) transduced with pBABEhCTLA4-hCD59 or pBABE vector alone were assayed for expression of CD59 and CTLA4. Briefly, cells were incubated with l0ug/ml anti CTLA4, ANC152.2 (Ancell, Bayport, MN) or with l0ug/ml of either of the anti-CD59 antibodies, BRAlOG or MEM43 (Biodesign, Kennebunk, ME) , for 30 min., at 4C, in 0.1 m 1 of Dulbecco's PBS (DPBS) containing 1% Fetal Bovine Serum (FBS) or Bovine Serum Albumin (BSA). Cells were washed with DPBS before incubation with FITC conjugated antibodies to mouse IgG (Zymed, So.San Francisco, CA).
Cells were analysed on a Becton Dickenson FACSORT (Becton Dickenson, Franklin Lakes, NJ). Phosphatidyl inositol phospholipase C (PI-PLC) enzymatically cleaves gpi-linked molecules from the surface of cells and therefore should cleave the hCTLA4-hCD59 and pCTLA4-hCD59 molecules from the transduced PAECs.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Fig. 4 depicts a FACS analysis that shows the phosphatidyl inositol phospholipase C (PI-PLC) mediated removal of CTLA4 and CD59 domains from transduced PAECs. . PI-PLC
Removal of CC. FACS analysis was performed as described above in Figure 3 with the following exceptions. Drug resistant populations of porcine aortic endothelial cells (PAECs) transduced with pBABEhCTLA4-hCD59, or pBABEpCTLA4-hCD59 or pBABE vector alone were assayed for expression of CD59. Briefly, cells were incubated with l0ug/ml of either of the anti-CD59 antibodies, BRAlOG or MEM43 (Biodesign, Kennebunk, ME) , for 30 min., at 4C, in 0.1 ml of Dulbecco's PBS (DPBS) containing 1% Fetal Bovine Serum (FBS) or Bovine Serum Albumin (BSA). Cells were washed with DPBS before incubation with FITC conjugated antibodies to mouse IgG (Zymed, So.San Francisco, CA). In addition, an aliquot of the cell lines were treated with PI-PLC, (Boehringer Mannheim GmbH, Indianapolis, IN) at 1U/ml for lhour at 37C, prior to antibody incubations and FACS analysis on a Becton Dickenson FACSORT (Becton Dickenson, Franklin Lakes, NJ).
Fig. ~ depicts the results of cell killing experiments in which porcine aortic endothelia cells (PAECs) that express the chimeric molecules are protected from human serum-induced complement-mediated cell lysis. 5 x 10 3 vector control or hCTLA4hCD59 cells were seeded into the wells of a flat bottom 96 well plate 24 hours ahead of time. Adherent cells were washed twice using HESS containing 1% BSA.
Cells were sensitized by incubating with a polyclonal anti-PAEC antibody (Cocalico, Reamstown, PA), followed by incubation with the intracellular dye, Calcein AM(Molecular Probes, Eugene, OR) in HBSS/BSA for 30 minutes at 37°C. Excess Calcein AM was removed with two additional washes. Normal human serum complement source (Sigma, St. Louis, MO) was added to a final concentration of 10, 20, or 40% in 0.05m1 volume diluted in HBSS and incubated for 1 hour at 37°C. Supernatants containing released calcein from complement lysed cells was transferred to a fresh flat bottom microtiter plate.
The remaining intact cells with retained calcein were lysed using 0.05m1 1 °/a SDS. Released and retained fractions were read on a cytofluor 2350 (Millipore, Bedford, MA) at 485nm. Data is presented as percent cell death.
Fig. 6 depicts a FACS analysis that proves that the CTLA4 domain of the chimeric molecules interacts with B7 found on the same PAECs. Co-Stimulation Assays.
The costimulatory capacity of the PAEC was assayed using a modified endothelial cell costimulation assay (S. E. Maher, K. Karmann, W. Min, C. C. W. Hughes, J. S.
Pober, A. L. M. Bothwell. 1996. J. Immunol. 157:3838). 5 x 10 4 pBABE vector controI
(Vector) or hCTLA4hCD59 (CC) PAECs were seeded of a 96 well plates (Becton Dickenson, Franklin Lakes, NJ) 24 hours prior to co-culturing with T cells.
The following reagents were added to final concentrations of Sug/ml antiCD28, or antiB7.2;
l0ug/ml antiCTLA4; or Sug/well sCTLA4Ig. Prior to the costimulation assay, monolayers were washed gently with DPBS three times, followed by the addition of 1 x 10 5 Jurkats or T
cells as responder cells in 0.09m1 of RPMI 1640 +FBS, and incubated for 30min at 37°C.
Phytohemagglutinin (PHA) was added in a O.Olml volume to a final concentration of l0ug/ml for 20hrs at 37°C. Cell free supernatants were collected 20 hours post treatment and assayed by ELISA (R&D Systems, Minneapolis, MN). Plates were read on a Microplate Reader 350 (Biorad, Hercules, CA) at 485nm. Jurkat supernatents were tested undiluted.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Fig. 7 depicts the human amino acid sequence of DAF.
Detailed Description It has been found that functional domains capable of regulating the humoral effector functions of the immune system including complement inhibitory domains, such as a CSb-9 inhibitory domains or C3 inhibitory domains, and functional domains capable of regulating the cellular effector functions of the immune system, including T Cell inhibitory domains, can advantageously be combined to form a chimeric protein. The chimeric protein can be expressed on a porcine cell surface and can aid in the protection of the porcine cell, after xenotransplantation into a human, from both the human cellular immune response and human complement.
As used herein. the phrase "CSb-9 inhibitory activity" is used herein to describe the effects of CSb-9 inhibitor molecules of the foregoing types on the complement system and thus includes activities that lead to inhibition of the cell activating and/or lytic function of the membrane attack complex (MAC).
Suitable domains which exhibit CSb-9 inhibitory activity can include the entire amino acid sequence for a naturally occurring CSb-9 inhibitor protein or a portion thereof. For example, the CSb-9 sequence can be the mature CD59 molecule (i.e., amino acids I through 103 of Fig. 2E(2) ). Alternatively, the CSb-9 sequence can be a portion of a naturally occurring CSb-9 inhibitor protein, such as CD59. Active portions suitable for use herein can be identified using a variety of assays for CSb-9 inhibitory activity known in the art. See for example Rollins, et al.. J. Immunol.
144:3478. 1990; Rollins, et al., J. Immunol. 146:2345, 1991; Zhao, et al., J.
Biol. Chem. 266:
13418, 1991; and Rother, et al., J. Virol. 68:730, 1994. In general, the portion used should have at least about 25% and preferably at least about 50% of the activity of the parent molecule.
Suitable C3 inhibitory domains include the entire amino acid sequence for a naturally occurring C3 inhibtor or a portion thereof, such as one or more SCRs of the C3 inhibitory domain.
For example, the C3 sequence can be the mature DAF molecule (factor H, membrane cofactor protein or complement recepor 1 ). Alternatively, the C3 inhibitory domain can be a portion of a naturally occurring C3 inhibitor protein. Following the procedures used to identify functional domains of DAF (Adams, et al., 1991. J. Immunol. 147:3005-3011), functional domains of other C3 inhibitors can be identified and used herein. In general, the portion used should have at least about 25% and preferably at least about 50% of the activity of the parent C3 inhibitory molecule.
Particularly useful portions of mature C3 inhibitor proteins include one or more of the mature molecule's SCRs. These SCRs are normally approximately 60 amino acids in length and have four conserved cysteine residues which form disulfide bonds, as well as conserved tryptophan, glycine, WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 and phenylalanine/tyrc, ..~e residues. In one embodiment the C3 inhib~. ~
domain includes SCRs 2 through 4 of DAF (i.e. amino acids 97 through 286 shown in figure 7).
Suitable domains which exhibits T Cell inhibitory activity can include either at least a portion of the amino acid sequence for naturally occurring porcine CTLA4 or at least a portion of the entire amino acid sequence for naturally occurring human CTLA4. For example, the amino acid sequence which exhibits T Cell inhibitory activity can be amino acids 38 to 162 of the porcine CTLA4 sequence shown in Fig. 2C(2) or amino acids 38 to 161 of the human CTLA4 sequence shown in Fig. 2D(2) In general, the portion used should have at least about 25% and preferably at least about SO% of the activity of the parent molecule.
The amino acid sequence having CSb-9 inhibitory activity and the amino acid secquence having T Ce(1 inhibitory activity do not have to be directly attached to one another. A linker sequence can separate these two sequences. The linker preferably comprises between about one and at least about 6 amino. Suitable linker sequences can include glycines.
Other amino acids, as well as combinations of amino acids, can be used in the linker region if desired. In one embodiment, amino acids 153 to 158 of Fig. 2A(2) (GGGGGG in pCC) are the linker sequence.
In another embodiment, amino acids 152 to 157 of Fig. 2B(2) (SASASA in hCC) are the linker sequence.
Another embodiment provides recombinant cDNA that encodes an exon of the human homologue of CTLA4 is inserted into the coding region of human CD59, bisecting CD59 between the leader peptide and the mature peptide post-translational processing site, see Fig. 2A( 1 ). A
further embodiment provides recombinant cDNA which that encodes an exon of the porcine homologue of CTLA4 is inserted into the coding region of human CD59, bisecting CD59 between the leader peptide and the mature peptide post-translational processing site, see Fig. 2B(1). In both embodiments, the cDNA may include a coding sequence for a GPI anchor linkage site corresponding to amino acid 210 of CC and amino acid 77 of native CD59, see Fig.'s 2A( 1 ) and 2B( 1 ).
Molecules comprising nucleotide sequences encoding the CTLA4 and CD59 or DAF
domains can be prepared using a variety of techniques known in the art. For example, the nucleotide sequences encoding the CTLA4 nucleotide # 112-483 and CD59 leader peptide region nucleotide 1-75 and mature peptide nucleotide 76-384 domains can be produced using PCR
generation and/or restriction digestion of cloned genes to generate fragments encoding amino acid sequences having T Cell and CSb-9 inhibitory activities. These fragments can be assembled using PCR fusion or enzymatic ligation of the restriction digestion products (Sambrook, et al., Molecular Cloning: A laboratory manual. 2"d edition. Cold Spring Harbor Press, 1989);
Ausubel et al.
Current Protocols in Molecular Biology. 1991 ). Alternatively, any or all of the nucleic acid fragments used to assemble the chimeric genes can be synthesized by chemical means. In another WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 embodiment. the nuclt _.de sequences encoding the CTLA4 and DA>~ ' .pains can be produced using PCR generation and/or restriction digestion of cloned genes to generate fragments encoding amino acid sequences having T Cell and C3 inhibitory activities. These fragments also can be assembled using PCR fusion or enzymatic ligation of the restriction digestion products (Sambrook.
et al., Molecular Cloning: A laboratory manual. 2"° edition. Cold Spring Harbor Press. 1989;
Ausubel et al., Current Protocols in Molecular Biology. 1991). Any or all of the nucleic acid fragments used to assemble these chimeric genes can be synthesized by chemical means as well.
In another embodiment, recombinant expression vectors which include nucleic acid fragments the chimeric protein are provided. The nucleic acid molecule coding for such a chimeric protein can be inserted into an appropriate expression vector, i.e., a vector that contains the necessary elements for the transcription and translation of the inserted protein-encoding sequence.
Suitable host vector systems include. but are not limited to, mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, retroviruses, etc.); mammalian cell systems transfected with plasmids; insect cell systems infected with virus (e.g., baculovirusl;
microorganisms such as yeast containing yeast expression vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA (see. for example, Goeddel, 1990). Commonly used promoters and enhancers derived from Polyoma virus, Adenovirus. Simian Virus 40 (SV40), the Molony murine leukemia virus (MMLV), including the long terminal repeat (MMLV-LTR), and human cytomegalovirus (CMV), including the cytomegalovirus immediate-early gene 1 promoter and enhancer are suitable. Eukaryotic promotors-BetaActin (Ng et al.) & H2Kb (Fodor et al. PNAS
1994) In a preferred embodiment, the cDNA of interest is cloned into a retroviral vector that is subsequently transfected into a mouse cell line called a "packaging line." The manipulation of retroviral nucleic acids to construct retroviral vectors and packaging cells is accomplished using techniques known in the art. See for example Ausubel, et al.. 1992. Volume 1, Section III
(units 9.10.1-9.14.3); Sambrook, et al., Molecular Cloning: A laboratory manual. 2"d edition.
Cold Spring Harbor Press, 1989; Miller, et al., Molecular and Cellular Biology 6:2895. 1986;
Eglitis, et al., Biotechniques. 6:608-614. 1988; U.S. Pat. Nos. 4,650,764, 4,861,719, 4,980,289, 5,122,767, and 5,124,263: as well as PCT Patent Publications Nos.
WO 85/05629, WO 89/07150, WO 90/02797, WO 90/02806, WO 90/13641, WO 92/05266, WO 92/07943, WO
92/14829, and WO 93/14188. Typically, the retroviral vector contains a gene that allows for selection via resistance to drugs such as puromyacin. It also contains nucleic acid sequence that allows for random or directed integration of the vector into a eukaryotic genome. Drug resistant cell lines are selected. These cells will produce virus particles capable of infecting other cells lines.
Porcine aortic endothelia cells (PAECs) are infected with the viruses by a process called viral transduction. The transduced PAECs are selected for by drug resistance. Drug resistant cells WO 01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 contain integrated copy ~f the viral vector DNA. Once in the porcine ge,._~ne, vector sequences or sequences associated with the chimeric gene control the expression of the chimeric protein.
In particular, the retroviral vectors of the invention can be prepared and used as follows.
First, a retroviral vector containing nucleic acid encoding for the chimeric protein described herein above is constructed and packaged into non-infectious transducing viral particles (virions) using an amphotropic packaging system, preferably one suitable for use in gene therapy applications.
Examples of such packaging systems are found in, for example, Miller, et al., Molecular and Cellular Biology 6:2895, 1986; Markowitz, et al., J. Virol. 62:1120-1124.
1988; Cosset, et al., J.
Virol. 64:1070-1078. 1999. U.S. Pat. Nos. 4.650,764, 4,861,719. 4,980.289, 5,122.767, and 5,124,263, and PCT Patent Publications Nos. WO 85/05629. WO 89/07150. WO
90/02797, WO
90/02806, WO 90/13641, WO 92/05266, WO 92/07943, WO 92/14829, and WO 93/14188.
A
preferred packaging cell is the PA317 packaging cell line (ATCC CRL 9078.
Rockville, MD). The Qeneration of "producer cells" is accomplished by introducing retroviral vectors into the packaging cells. The producer cells generated by the foregoing procedures are used to produce the retroviral vector particles (virions). This is accomplished by culturing of the cells in a suitable growth medium. Preferably, the virions are harvested from the culture and administered to the target cells which are to be transduced. Examples of such retroviral vectors are found in, for example, Korman, et al., Proc. Natl. Acad. Sci. USA. 84:2150-2154. 1987: Morgenstern, et al.. Nucleic Acid Research 18:3587. 1990; U.S. Pat. Nos. 4,405,712. 4,980,289, and 5,112,767: and PCT
Patent Publications Nos. WO 85/05629, WO 90/02797, and WO 92/07943. A
preferred retroviral vector is the MMLV derived expression vector pLXSN (See Miller, et al., Biotechniques. 7:981 1989). DNA can be introduce into cells by any standard method of transfection such as polybrene, DEAF, calcium phosphate, lipofection. electroporation. (See Sambrook, et al., Molecular cloning:
a laboratory manual. Second Edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, N.Y. 1989 ) Engineered transgenic animals (for example, rodent, e.g., mouse, rat, capybara, and the like, lagomorph, e.g., rabbit, hare, and the like, ungulate, e.g., pig, cow, goat, sheep, and the like, etc.) that express the chimeric protein described herein on the surfaces of their cells are provided using any suitable techniques known in the art. These techniques include, but are not limited to, microinjection, e.g., of pronuclei, electroporation of ova or zygotes, nuclear transplantation, and/or the stable transfection or transduction of embryonic stem cells derived from the animal of choice.
A common element of these techniques involves the preparation of a transgene transcription unit. Such a unit includes a DNA molecule which generally includes: 1 ) a promoter, 2) the nucleic acid sequence, and 3) a polyadenylation signal sequence. Other sequences, such as, enhancer and intron sequences, can optionally be included. The unit can be conveniently prepared by isolating a restriction fragment of a plasmid vector which expresses the CTLA4-CD59 protein in, for 6 ~ 02361646 2001-07-30 pCT~S00/29151 example, mammalian . .s. rreferably. the restriction fragment is free o.
acterially derived sequences that are known to have deleterious effects on embryo viability and gene expression.
The most well known method for making transgenic animals is that used to produce transgenic mice by superovulation of a donor female, surgical removal of the egg, injection of the transgene transcription unit into the pro-nuclei of the embryo, and introduction of the transgenic embryo into the reproductive tract of a pseudopregnant host mother, usually of the same species.
See for example U.S. Pat. No. 4,873,191, Brinster. et al.. 1985. Proc. Natl.
Acad. Sci. USA.
82:4438-4442.. Hogan, et al., in "Manipulating the Mouse Embryo: A Laboratory Manual". Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1986. , Robertson. 1987.
in Robertson.
ed. "Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRI.
Press, Eynsham.
Oxford, England, Pedersen, et al., 1990. "Transgenic Techniques in Mice--A
Video Guide", Cold Spring Harbor Laboratory, Cold Spring Harbor. N.Y.
The use of this method to make transgenic livestock is also widely practiced by those of skill in the art. As an example, transgenic swine are routinely produced by the microinjection of a transgene transcription unit into pig embryos. See, for example, PCT
Publication No.
W092/11757. In brief, this procedure may, for example, be performed as follows. First, the transgene transcription unit is gel isolated and extensively purified through, for example, an ELUTIP column (Schleicher & Schuell, Keene, N.H.), dialyzed against pyrogen free injection buffer ( 10 mM Tris, pH 7.4+0.1 mM EDTA in pyrogen free water) and used for embryo injection.
Embryos are recovered from the oviduct of a hormonally synchronized, ovulation induced sow, preferably at the pronuclear stage. They are placed into a 1.5 ml microfuge tube containing approximately 0.5 ml of embryo transfer media (phosphate buffered saline with 10% fetal calf serum). These are centrifuged for 12 minutes at 16.OOO×g in a microcentrifuge. Embryos are removed from the microfuge tube with a drawn and polished Pasteur pipette and placed into a 35 mm petri dish for examination. If the cytoplasm is still opaque with lipid such that the pronuclei are not clearly visible, the embryos are centrifuged again for an additional 1 S
minutes. Embryos to be microinjected are placed into a drop of media (approximately 100 µl) in the center of the lid of a 100 mm petri dish. Silicone oil is used to cover this drop and to fill the lid to prevent the medium from evaporating. The petri dish lid containing the embryos is set onto an inverted microscope equipped with both a heated stage (37.S°-38° C.) and Hoffman modulation contrast optics (200× final magnification). A finely drawn and polished micropipette is used to stabilize the embryos while about 1-2 picoliters of injection buffer containing approximately 200-500 copies of the purified transgene transcription unit is delivered into the nucleus, preferably the male pronucleus, with another finely drawn and polished micropipette. Embryos surviving the microinjection process as judged by morphological observation are loaded into a polypropylene tube (2 mm m) for transfer into the recipient pseudopregnant sow. Offspring are tested for the WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 presence of the transgt by Isolating genomic DNA from tissue remov. :rom the tail of each piglet and subjecting about ~ micrograms of this genomic DNA to nucleic acid hybridization analysis with a transgene specific probe. In a preferred embodiment, transgenic animals are produced according to the methods disclosed in PCT Publicaton No. WO/9907829, the contents of which are incorporated herein by reference.
Another commonly used technique for generating transgenic animals involves the genetic manipulation of embryonic stem cells (ES cells) as described in PCT Patent Publication No. WO
93/02188 and Robertson, in Robertson. ed. "Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press, Eynsham, Oxford, England 1987. In accordance with this technique, ES cells are grown as described in, for example, Robertson. in Robertson. ed.
"Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press, Eynsham.
Oxford, England; 1987, and in U.S. Pat. No. 5,166,06 to Williams et al.
Genetic material is introduced into the embryonic stem cells by, for example, electroporation according, for example, to the method of McMahon, et al., Cell. 62:1073; 1990, or by transduction with a retroviral vector according, for example, to the method of Robertson, et al., Nature. 323:445;
1986, or by any of the various techniques described by in Robertson. ed. "Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press, Eynsham, Oxford, England, 1987.
Chimeric animals are generated as described, for example, in Bradley, in Robertson. ed.
"Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press. Eynsham, Oxford.
England. 1987.
Brietly, genetically modified ES cells are introduced into blastocysts and the modified blastocysts are then implanted in pseudo-pregnant female animals. Chimeras are selected from the offspring, for example by the observation of mosaic coat coloration resulting from differences in the strain used to prepare the ES cells and the strain used to prepare the blastocysts, and are bred to produce non-chimeric transgenic animals.
Other methods for the production of transgenic animals are disclosed in U.S.
Pat. No. 5,032,407 and PCT Publication No. W090/08832.
In order that those skilled in the art may be better able to practice the compositions and methods described herein, the following examples are given an illustration of the preparation of chimeric proteins having both complement inhibitory domains and T Cell inhibitory domains, as well as their ability to be expressed on a cell surface of an antigen presenting cell, bind targets on the same antigen presenting cell, and exhibit T Cell inhibitory activity. It is to be understood that commercially available reagents and/or instrumentation referred to in the examples were used according to the manufacturer's instructions unless otherwise indicated.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Example I
Construction of human CTLA4-human CD59 chimeric molecules A full length human CTLA4 cDNA was isolated from human peripheral blood leukocytes (PBLs) that were activated with 3ng/ml phorbol 12 myristate 13 acetate (PMA) and 0.4ug/ml ionomycin (commercially available from Sigma, St. Louis. MO). First strand cDNA synthesized from PBL RNA using reverse transcriptase as recommended by the vendor(Seikagaku America, Inc., Rockville, MD) was used as a template in a polymerase chain reaction (PCR) to amplify the extracellular domain encoded by exon 2 (according to methods desrcibed in Brunet, et al, "A
Differential Molecular Biology Search for Genes Preferentially Expressed in Functional T
Lymphocytes: The CTLA Genes". Immunol. Rev. 103:? I-36 ( 1988), and Dariavach, et al, ''Human Ig Superfamily CTLA-4 Gene: Chromosomal Localization and Identity of Protein Sequence Between Murine and Human CTLA-4 Cytoplasmic Domains." Eur. J.
Immunol.
18:1901-1905 (1988).). The 5' forward oligonucleotide:
~'GCCTGCAGATGCACGTGGCC3' and the 3' reverse oligonucleotide;
5'GGCTGCAGGGAGGCGGAGGCGGAGGCGTCAGAATCTGG3', which contained homologous nucleotides and nucleotide encoding linker sequence, were used in the following PCR reaction mixture to amplify a 406 base pair CTLA4 DNA fragment. Five microliters of a first strand synthesis of cDNA made from activated PBLs was amplified in the presence of l OmM
magnesium chloride, SOOmM dNTPs, 2uM oligonucleotides, 2.5 Units Taq polymerase (Perkin Elmer, Norwalk, CT) for forty cycles. Each cycle consisted of denaturing for one minute at 95°C, annealing at 55°C for one minute, and polymerizing at ?2"C for one minute. One cycle of polymerization at 72°C for ten minutes insured the addition of thymidine overhang for TA cloning.
The CTLA4 exon 2 fragment was ligated into the pCRII.ITOPO vector using the TOPO TA
cloning kit (commercially available from lnvitrogen, Carlsbad, CA) and used to transform the TOP
strain of E.Coli (commercially available from Invitrogen, Carlsbad. CA).
Plasmids containing the appropriately sized fragment were isolated and the inserts were subjected to DNA sequencing to confirm the integrity and identity of the DNA ( Wm. Keck Foundation Biotechnology Resource Laboratory Yale University, New Haven, CT). Plasmids that contained the verified CTLA4 exon 2 insert were digested with Pstl and the 406bp CTLA4 exon 2 fragment was isolated. A GEM7Z
plasmid (commercially available from Clontech, Palo Alto, CA) that contained the human CD59 sequence (gift from Dr. A. Bothwell, Yale University) that has a unique PstI
site located between the human CD59 signal sequence and mature protein coding sequence was digested with PstI. The PstI fragment that contained CTLA4 exon 2 was ligated into the corresponding PstI site on GEM7Z and plasmids that contained the correct insert were selected.
A BamHI-EcoRI fragment containing the entire chimeric human CTLA-human CD59 (hCTLA4hCD59) gene was excised from the plasmid and then subcloned into the amphitropic retroviral expression vector pBABEpuro (Morganstem, et all to generate the expression vector hCTLA4hCD59BABEpuro.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Example II
Cloning of porcine CTLA4 Porcine cDNA was prepared from porcine PBLs that were activated with 3ng/ml PMA and 0.4ug/ml ionomycin (commercially available from Sigma, St. Louis. MO). The cDNA was used as a template in a PCR using redundant primers designed from a comparison of human t Genbank accession # NM005214), mouse (X05719), rabbit (D49844), and bovine (X93305) nucleotide sequences. The 5' foreward oligonucleotide:
5'CCCMYMAGCCATGGCTYYYGG3' together with the 3' reverse oligonucleotide:
~'CCTCARTTRATRGGA4AAAATAAGGTG3' were used in PCR conditions as described in Example I, except annealing occurred at 4~C, and twenty cycles of amplification were used.
The PCR produced a 672 base pair fragment that was cloned into the TOPO vector using the TOPO
TA cloning kit (commercially available from Invitrogen, Carlsbad, CA1. DNA
Sequence analysis confirmed that the insert was the full-length porcine CTLA~ clone.
Example III
Construction of porcine CTLA4-human CD59 chimeric molecules The extracellular domain of porcine CTLA4 encoded by exon 2 was PCR
amplified from the TOPO plasmid prepared in Example II using a 5' foreward oligonucleotide:
5'CCATGCATAT GCACGTGGCC CAGCCTGCAG, and a 3' oligonucleotide: 5'CATGCATGCC ACCGCCACC GCCACCGAAA TCAGAATCTG
GGCATGGTTC TGGATCAATG3' that contained homologous pCTLA4 sequence restriction sites and linker sequence using the same PCR conditions as described in Example I, except that only 35 cycles of amplification were used to generate a 393 base pair DNA
fragment. The fragment was cloned into the TOPO vector using the TOPO TA cloning kit (commercially available from Invitrogen, Carlsbad, CA). DNA sequence analysis confirmed that the insert was the porcine CTLA4 exon 2. The plasmid was digested with Nsi I and the fragment that contained the CTLA4 exon 2 was isolated and ligated into the PstI site of the GEM7Z plasmid that contained human CD59 as described in Example I. The BamEl-EcoRl fragment containing the chimeric pig CTLA~-human CD59 molecule (pCTLA4hCD59) was excised from the plasmid and then subcloned into the amphitropic retroviral expression vector pBABEpuro (See Morgenstern, et al., Nucleic Acids Res. 18:3587 1990.) to generate the expression vector pCTLA4hCD59BABEpuro.
Example IV
Cell surface expression of hCTLA4-hCD59 chimeric molecules To create a cell line that expresses the human CTLA4-humanCD59 chimeric molecule a cell line must be created that produces retroviral vectors that contain the necessary gene. Another cell line must then be transduced with the virus to create a population of cells that express the protein.
To produce the retrovirus, the murine amphitropic packaging cell line PA317 (ATCC, Rochville, MD) was transfected with the expression vector prepared in Example I
(hCTLA4hCD59BABEpurol , example 3 or BABEpuro (vector control DNA) by the polybrene method (See Sambrook, et al., Molecular cloning: a laboratory manual. Second Edition. Cold Spring Harbor Labora..,ry Press, Cold Spring Harbor, N.Y. 1989.) Te,, micrograms of DNA
were added to PA317 cells in ~ml of Dulbecco minimum essential medium (DMEM) .
available from Cellgro, Herndon. VA. containing 10% heat inactivated fetal bovine serum (FBSI followed by a five hour treatment with 30mg/ml polybrene (Sigma. St.Louis. MO) , without a dimethylsufoxide (DMSO) shock. The cells were washed and incubated in DMEM
with 10% FBS
and 48 hours post transfection, the cells were treated with 3mg/ml puromycin to select drug resistant transfectants. The transfected PA317 cells produced retrovirus and viral supernatents which were harvested as described by Morgenstern, et al. Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper free packaging cell line. 1990. Nucleic Acid Research. 18:3587. The next step was to transduce porcine cells to create a porcine cell line that expresses human CTLA4-humanCD59 protein and the porcine CTLA4-hCD59. Using standard methods 5 x 105 porcine aortic endothelial cells (PAEC) were transduced using 1.5 ml of viral supenatent added to 3.~ ml of DMEM with 10% FBS followed by the addition of polybrene to 8 mg/ml for 5 hours. Following transduction the cells were incubated in DMEM with 10% FBS for 48 hours. The cells were split into selection medium (DMEM with 10% FBS and 3ug/ml puromycin). Puromycin resistent cell populations that express human CTLA4-human CD59 chimeric molecules were identified by florescence activated cell sorting (FACS) analysis using antibodies to human CTLA4 and human CD59 using standard methodologies (Current Protocols in Immunology, ed. J. E.
Coligan, et al).
Populations of PAEC transduced with hCTLA4hCD59BABEpuro, pCTLA4hCD59 or BABEpuro vector alone were assayed for cell surface expression of CD59 and CTLA4 by FACS analysis using antibodies to human CTLA4 and human CD59. Briefly, cells were incubated with l Omg/ml anti CTLA4 (commercially available from Ancell. Bayport. NIN) for 30 min., at 4°C. in 0. I ml of Dulbecco's phosphate buffered saline (DPBS) containing 1 % FBS or bovine serum albumin (BSA). Cells were washed with DPBS before incubation with FITC conjugated antibodies to mouse IgG (commercially available from Zymed, Co., San Francisco, CA). FACS
analysis was carried out on a Becton Dickenson FACSORT (Becton Dickenson, Franklin Lakes, NJ) instrument using standard methodologies ( Current Protocols in Immunology, Ed.
J.E.Coligan). The pBABEpuro transduced cells were negative for hCTLA4 expression (Figure 3). The hCTLA4hCD59 PAECs exhibited high level expression of hCTLA4 and hCD59 as determined by FACS analysis with antibodies specific to each moiety (Fig. 3 and Fig. 4).
The hCTLA4hCD59 cell line was also treated with PI-PLC and then assayed for expression of the chimeric molecule to further demonstrate that the chimeric molecules were anchored to the cell surface with a CD59 GPI anchor linkage, by enzymatically cleaving the CD59 GPI membrane attachment. Figure 4 illustrates the loss of cell surface expression following PIPLC treatment, as indicated by reduced antibody reactivity following enzymatic digestion.
Example V
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Cell surface expression. ~i pL rLA4-hCD59 chimeric molecules Production of a PAEC line to express pCTLA4hCD59 was carried out in the same manner as described in Example IV, however the DNA used to transfect the virus producing cell line was the expression vector pCTLA4hCD59BABEpuro prepared in Example III. FACS analysis for cell surface expression was carried out as described in Example IV. However, detection of the pCLTA4 had to be accomplished by a different method because the human specific anti CTLA4 antibody, ANC152.2, only bound to the human CTLA4 molecule and did not cross react to the pig molecule (data not shown). Therefore, the pCTLA4-hCD59 molecule was detected with the anti CD59 mAb, BRAIOG or MEM 43 (Biodesign, Kinnebunk. ME). Figure 4 illustrates expression on hCTLA4-hCD59 and pCTLA4-hCD59 transduced PAEC.
The pCTLA4hCD59 cell line was also treated with PI-PLC and then assayed for expression of the chimeric molecule to demonstrate that the chimeric molecules were anchored to the cell surface with a CD59 GPI anchor linkage by cleaving the CD59 GPI membrane attachment. Fig. 4 illustrates the loss of cell surface expression following PI-PLC treatment.
Both moieties could not be detected post digestion.
Example VI
Demonstration of human CD59 activity in the hCTLA4-hCD59 chimera To determine if the CD59 moiety was functional, complement-mediated killing assays were performed using normal human serum as a source of complement. PAECs (5 x 103) transduced with vector control or hCTLA4hCD59 were seeded into the wells of a flat bottom 96 well plates.
After 24 hours adherent cells were washed twice using Hanks balanced salt solution (HBSS) containing 1 % BSA (HBSS/BSA). Cells were sensitized by incubating with a polyclonal anti-PAEC antibody ( Cocalico, Reamstown, PA), followed by incubation with the intracellular dye, Calcein AM (commercially available from Molecular Probes, Eugene, OR) in HBSS/BSA for 30 minutes at 37°C. Excess Calcein AM was removed with two additional washes. Normal human serum (commercially available from Sigma, St. Louis, MO) was used as a complement source and was added to a final concentration of 10%, 20%, or 40% in O.OSmI volume diluted in HBSS and the cells were incubated for 1 hour at 37°C. Supernatants containing released calcein from complement lysed cells was transferred to fresh flat bottom microtiter plates.
The remaining intact cells with retained calcein were lysed using O.OSmI 1 % sodium dodecylphosphate (SDS). The optical density (OD) at 485 nm was determined for all samples using a cytofluor 2350 spectrophotometer (commercially available from Millipore, Bedford, MA). The percent cell death is determined by comparing the OD obtained from untreated cells to that obtained from treated cells. Figure 5 illustrates the percentage of cell death due to increasing concentrations of human WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 serum. Vector transdu,..;d P.yECs were susceptible to human serum in ~ .pose dependent manner.
However, hCTLA4hCD59 PAECs were 2-3 fold more resistant to human serum induced cell lysis at all concentrations of serum tested as compared to control PAECs.
Example VII
Demonstration of human CTLA4 activity in the hCTLA4-hCD59 chimera When antigen presenting cells (APC) such as PAECs are co-cultured with Jurkat cells, a human T-cell line ATCC TIB 152 or human T cells (responder cells) a costimulatory signal results that elicits interleukin 2 (IL-2) production from the responder cells.
Therefore, to test the function of the hCTLA4 molecule in the context of the chimeric molecule, costimulation assays were performed using Jurkat cells as responder cells and vector control, hCTLA4hCD59 PAECs or pCTLA4-CD59 as APCs, respectively. The costimulatory capacity of the various PAECs was assayed using a modified endothelial cell costimulation assay (as described in Maher. et al., Journal of Immunology, 157:3838 1999 ). PAECs transduced with pBABE vector control, hCTLA4hCD59, or pCTLA4-hCD59 were seeded at 5 x 104 cells per well in 96 well plates (commercially available from Becton Dickenson, Franklin Lakes, NJ) 24 hours prior to coculturing with T cells. The following reagents were added to final concentrations of Sug/ml for antiCD28, or antiB72(see for example); l0ug/ml antiCTLA4 (Ancell, Bayport, MN); or Sug/well sCTLA4Ig(Ancell, Bayport, MN). Prior to the costimulation assay, monolayers were washed gently with DPBS three times, followed by the addition of I x 105 Jurkats or T
cells as responder cells in 0.09m1 of (spell out RPMI) (RPMI 1640) with FBS, and incubated for 30min at 37°C
PHA, phytohemaglutinin (Sigma L7019) was added in a O.lml volume to a final concentration of lOmg/ml for 20hrs, at 37°C. Cell free supernatants were collected 20 hours post treatment and assayed for IL-2 by enzyme linked immunosorbant assay (ELISA) (commercially available from R&D Systems, Minneapolis, MN). Optical density (OD) at 485nm was determined using a Microplate Reader 3550 (commercially available from Biorad, Hercules, CA) and the OD is proportional to IL-2 production and determined by comparison to a calibration curve generated with known amounts of IL-2. Jurkat supenatents were tested undiluted.
IL-2 release from stimulated Jurkat cells is depicted in Figure 6. The amount of IL-2 elicited from Junket cells in the presence or absence of pig aortic endothelial cells as antigen presenting cells requires primary and secondary stimulatory signals. Without the secondary co-stimulatory signal provided by an APC or anti CD28, Jurkats remain unactivated, and secrete little to no IL2.
The assay utilizes the lectin, phytohemaglutinin (PHA) to cross-link the T
cell receptor complex and stimulate the primary signal. When both the primary and secondary signals are provided, 446pg/ml of IL-2 is secreted. If the secondary signal is provided by vector control PAEC as APC
instead of anti CD28, 406pg/ml IL-2 is secreted. An antibody to pig B7.2 blocks the secondary signal and therefore IL,-2 production by specifically binding to the B7.2 molecules on the APC
thereby blocking the co-stimulatory second signal. CTLA4 is an alternate ligand for B7.1 and WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 B7.2 and has a ten to twenty told higher binding affinity than CD28.
T~..,refore. using a soluble form of CTLA4, shCTLA4Ig binds to B7 on PAEC preventing binding of CD28 on Jurkats resulting in no secondary signal. If the secondary signal is provided by an APC bearing the hCTLA4-hCD59, a huge reduction is seen in the secretion of IL-2 to 69pg/ml, nearly to levels attained with anti pB7.2 or shCTLA4. CTLA4 in the chimeric molecule binds B7.2 in cis preventing Jurkats from CD28 engagement. A blocking antibody to hCTLA4 specifically binds the CTLA4 mioety of the hCTLA4-hCD59 molecule and prevents it from binding to pB7.2 on the CCPAEC surface. B7.2 is therefore available to bind CD28 on Jurkat cells leading to activation and IL-2 secretion. HCTLA4-hCD59 is a gpi linked molecule and. can be cleaved off the cell surface of the cells by phosphotidyl inositol phospholipase C. When hCTLA4-hCD59 is removed the secondary signal is restored, and the Junket cells become activated and secret IL-2.
REFERENCES
The following references are incorporated herein by reference to more fully describe the state of the art. All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
A. Aruffo, B. Seed. 1987. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. PNAS 84:8573. (cloning CD28) A. S. B. Edge, M. E. Gosse. J. Dinsmore. 1998. Xenogeneic cell therapy: cur-rent progress and future developments in porcine cell transplantation. Cell Transpl. 7:525.
Adams. et al., 1991. "Contribution of the Repeating Domains of Membrane Cofactor Protein (CD46) of the Complement System to Liaand Binding and Cofactor Activity"
Journal of Immunology 147:3005-301 1.
Albrecht, et al., 1992. "Herpesvirus Saimiri Has a Gene Specifying a Homologue of the Cellular Membrane Glycoprotein CD59" Virology 190:527-530.
Allen, "Antigen Processing at the Molecular Level", Immunol. Today 8:270-273 ( 1987).
Aruffo and Seed, "Molecular Cloning of a CD28 cDNA by a High-Efficiency COS
Cell Expression System", Proc. Natl. Acad. Sci. 84:8573-8577 (1987).
Auchincioss Jr., H., R. Lee, S. Shea, J. S. Markowitz, M. J. Grusby, L. H.
Glimcher. 1993.
The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class 11-deficient mice. PNAS 90:3373.
Auchincloss, H. ( 1988) Xenogeneic transplantation. A review. Transplantation 46,1-20.
Auchincloss, H. (1998) Xenogeneic transplantation. Annu. Rev. Immunol. 16.433-B.R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari. G. S. Gray, D. A. Vallera.
1995.
Coblockade of the LFAI:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex- disparate donor grafts. Blood. 9:2607.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Ausubel, F.M., B._.~t, tc., Kingston. R.E., Moore, D.D., Seidma._. J.G., Smith. J.A..
Struhl. K. eds., Current Protocols in Molecular Biology. 1991.
Bach. F. H., Turinan, M. A.. Vercelloti. G. M.. Platt. J. L.. and Dalmasso, A.
P. ( 1991 Accomodation: a working paradigm for progressing toward discordant xenografting.
Transplant. Proc. 23,205-208 Brunet et al., "A Differential Molecular Biology Search for Genes Preferentially Expressed in Functional T Lymphocytes: The CTLA Genes", Immunol. Rev. 103:21-36 ( 1988).
Brunet et al., "A New Member of the Immunoalobulin Superfamily-CTLA-s", Nature 328:267-270 ( 1987). ~ .
Byme, G. W., McCurry, K. R., Martin, M. J., McClellan. S. M.. Platt. J. L., and Logan, J.
S. ( 1997) Transgenic pigs expressing human CD59 and decay accelerating factor produce an intrinsic barrier to complement-mediated daTnage. Transplantation 63, 149-155 C. A. Bravery, P. Batten. M. H. Yacoub, M. L. Rose. 1995. Direct recognition of SLA- and HLA- like class 11 antigens on porcine endothelium by human T cells results in T cell activation and release of interleukin-2. Transpl. 60:1024.
C. B. Thompson. T. Lindsten. J. A. Ledbetter, S. L. Kunkel, H. A. Young S. G.
Emerson.
J. M. Leiden, C. H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell- derived lymphokines/cytokines. PNAS 84:1333. (IL-2 secretion due to C. F. Morris. C. J. Simeonovic, M. Fung, J. D. Wilson, A. J. Hapel. 1995.
Intragraft expression of cytokine transcripts during pig proislet xenograft rejection and tolerance in mice.
J. Immunol. 154:2470. (CD4+T mediate xenorejectionl C. H. June. J. A. Ledbetter, P. S. Linsley, C. B. Thompson. 1990. Role of CD28 receptor in T cell activation. Immunol. Today 1 1:21 1.
Chahine, A. A., M. Yu, M. M. McKeman. C. Stoechert, H. T. Lau. 1995.
Immunomodulation of pancreatic islet allografts in mice with CTLA41 g secreting muscle cells.
Transpl. 59:1313.
Chen. C. G., Fisicaro, N., Shinkel, T. A., Aitken, V., Katerelos, M., van Denderen, B. J.
W., Tange, M. J., Crawford. R. J.. Robins. A. J., Pearse. M. J., and D'Apice.
A. J. F.
( 1996) Reduction in Gal- alpha 1.3-Gal epitope expression in transgenic mice expressing human Htransferase. Xenotransplantation 3. 69-75 Chen. C. G., Salvaris. E. J.. Romanella, M., Katerelos, M.. Fisicaro, N., Aminian, A., D'Apice, A. J. F., and A. J., Pearse. M. J. ( 1996) Trans~enic expression of human ocl,2fucosyltransferase (H- transferase) prolongs mouse heart survival in an ex vivo model of xenograft rejection. Transplantation 6~. 832-837 Clark et al., "Polypeptides on Human B Lymphocytes Associated with Cell Activation", Human Immunol. 16:100-113 (1986).
Cohney, S.. McKenzie, 1. F. C., Patton, K.. Prenzoska, J.. Ostenreid, K., Fodor, W. I
Costa, C., Zhao, L., DeCesare. S., and Fodor, W. L. Comparative analysis of three genetic modifications designed to inhibit human serum-mediated cv_ tolysis.
Xenotransplanration (in press).
Coligan, J.E.. Kruisbeek, A.M., Margulies. D.H., Shevach, E.M., Strober, W.
eds. 1992.
Current Protocols in Immunology. J.Wiley and Sons, NY.
Cowan" P. J., Chen, C. G., Shinkel, T. A.. Fisicaro, N., Salvaris, E., Aminian, A., Romanella, M., Pearse, M. J., and D'Apice. A. J. F. (1998) Knock-out of a1,3-galactosyltransferase or expression of ccl,2-fucosyltransferase further protects CD55- and CD59-expressing mouse hearts in an ex vivo model of xenograft rejection.
Transplantation 65.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Coyne et al., 199. Mapping of epitopes, glycosylation sites, and ~~~nplement regulatory domains in human decay accelerating factor," Journal of Immunology 149:2906-2913.
Cozzi, E. Yannoutsos, N., Langford, G. A., Pino-Chavez, G., Wallwork, and White, D. J.
G. (1997) Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In Xenotransplantation (Cooper. D. K.
C.and Kemp, E., eds) pp 665-682, Springer-Verlag, Berlin, Heidelberg Cramer, D. V. ( 1996) Natural antibodies. In Transplantation biology: cellular and molecular aspects. (Tilney, N. L., Strom, T. B., Paul, L. C., eds) pp 473-481, Raven Press, New York CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med.
174:561.
Dalmasso. A. P., Vercellotti, G. M., Platt. J. L., and Bach, F. H. ( 1991 ) Inhibition of complement- mediated endothelial cell cytotoxicity by decay-accelarating factor.
Tran.spLantation 52, 530-533 Dalmasso, A. P., Vercelotti. G. M., Fischel, R. J., Bolman, R. M. Bach. F. H., and Platt, J.
L. ( 1992) Mechanism of complement activation in the hyperacute rejection of porcine organs in primate recipients. Arn. JPathol. 140, 1157-1 166 Dalrnasso, A.P. et al. (1991) "Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor" Transplantation X2(3):530-533.
Damle et al., "Alloantigen-Specific Cytotoxic and Supressor T Lymphocytes are Derived from Phenotypically Distinct Precursors", J. Immunol. 131:2296-2300 ( 1983).
Damle et al., "Immunoregulatory T Lymphocytes in Man", J. Immunol. 139:1501-( 1987).
Damle et al., "Monoclonal Antibody Analysis of Human T Lymphocyte Subpopulations Exhibiting Autologous Mixed Lymphocyte Reaction", Proc. Natl. Acad. Sci.
78:5096-5098 (1981).
Dariavach et al., "Human Ig Superfamily CTLA-4 Gene: Chromosomal Localization and Identity of Protein Sequence Between Murine and Human CTLA-4 Cytoplasmic Domains."
Eur. J. Immunol. 18:1901-1905 (1988).
Davies. et al., 1989. "CD59, an LY-6-like protein expressed in human lymphoid cells.
regulates the action of the complement membrane attack complex on homologous cells" J. Exp.
Med. 170:637-654.
Davis, E. A., Pruitt, S. K., Greene, P. S., Ibrahim, S., Lam, T. T., Levin, J.
L., Baldwin I 11, W. M., Sanfilippo, F. ( 1996) Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts.
Transplantation 62. 10181023 Diamond, L. E., McCurry, K. R., Martin, M. J., McClellan, Oldham, E. R., Platt. J. L., and Logan, J. S. ( 1996) Characterization of transgenic pigs expressing fimctionally active human CD59 on cardiac endothelium. Transplantation 61, 1241-1249 Fodor, W. L., Williams, B. L., Matis, L. A., Madri, J. A., Rollins, S. A., Knight, J. W., Velander, W., and Squinto, S. P. (1994) Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl. Acad. Sci. USA 9I. I 1153-11157 Galili, U. ( 1993) Evolution and pathophysiology of the human anti-a-galactosyl IgG (antiGal) antibody. SpringerSemin. ImmunopathoL 15,155-171 Gallili U. ( 1997) Anti-agalactosyl (Anti-Gal) antibody damage beyond hyperacute rejection. In Xenotransplantation (Cooper, D. K. C.and Kemp, E.. eds) pp 95-103, Springer-Verlag, Berlin, Heidelberg Goodman, D. J., Millan, M. T., Ferran, C., and Bach, F. H. (1997) Mechanisms of delayed xenograft rejection. In Xenotransplantation (Cooper, D. K. C.and Kemp, E., eds) pp 95-103, Springer-Verlag, Berlin, Heidelberg WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 H. Auchincloss, J. , D. t-~. Sachs. 1998. Xenogeneic transplantatic,, . Ann.
Rev. Immunol.
I 6:433.
Hancock, W. W., M. H. Sayegh, X. Zheng, R. Peach. P. S. Linsley, L. A. Turka.
1996.
Costimulatory function and expression o CD40 ligand. CD80, and CD86 in vascularized murine cardiac allograft rejection. PNAS 93:13967.
Harper. K., C. Balzano. E. Rouvier, M. Mattei, M. Luciani. P. Golstein. 1991.
and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J.
hmmmol.
147:1037.
Hayes, C. E., and Goldstein, 1. J. (1974) An a-D-galactosyl-binding lectin from Bandeir-aea simplicifolia seeds. J BioL Chem. 249. 1904- I 914 Higgins, P.J.,Ko.J.L., Lobell.R., Sardonini,C., Alessi,M.K.. Yeh, C.G. 1997.
J.1. 158:
287281. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities.
Inverardi. L., Clissi, B., Stolzer. A. L.. Bender, J. R.. Sandrin. M. S., and Pardi. R. ( 1997) Human natural killer lymphocytes directly recognize evolutionary conserved oliQosaccharide ligands expressed by xenogeneic tissues. Transplantation 63. 1318-1330 J. A. Bluestone. 1997. Is CTLA-4 a master switch for peripheral T cell tolerance? J. Irnmunol.
158:1989.
June et al., "T-Cell Proliferation Involving the CD28 Pathway is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", Mol. Cell. Biol. 7:4472-4481 ( 1987).
K. lwata, T. Seya, H. Arita, S. Nagasawa. 1994. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein. J. Immunol. 152:3436.
Kalli, K.R. et al. (1991) "Mapping of the C3b-binding Site of CRl and Constmction of a (CRl)2-F(ab')2 Chimeric Complement Inhibitor." J. Exp. Med. 174:1451-1460.
Kennedy, S. P., Rollins, S. A., Burton, W. V., Sims, P. J., Bothwell. A. L.
M., Squinto. S.
P., and Zavoico, G. B. ( 1994) Protection of porcine aortic endothelial cells ftom complementmediated cell lysis and activation by recombinant human CD59.
Transplantation 57, 14941501 Kohno et al., "CD28 Molecule as a Receptor-Like Function for Accessory Signals in Cell-Mediated Augmentation of IL-2 Production", Cell Immunol. 131:1-10 ( 1990).
Koike, C., Kannagi, R., Takuma, Y., Akutsu. F., Hayashi. S., Hiraiwa, N., Kadomatsu, T., Murainatsu, T., Yarnakawa, H., Nagai, T., Kobayashi. S., Okada, H., Nakashima, L, Uchida, K., Yokoyama, L, and Takagi, H. (1996) Introduction of cc(1,2)-fticosyltransferase and its effect on (x-Gal epitopes in transgenic pig. Xenotransplantation 3. 81-Kroshus, T. J., Bohnan I 11, R. M., Dalmasso, A. P., Rollins, S. A., Guilmette, E. R., Williarns, B. L., Squinto, S. P., and Fodor. W. L. ( 1996) Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perftision model.
Transplantation 61, 1513- 1521 Lafage-Pochitaloff et al., "Human CD28 and CTLA-4 Ig Superfamily Genes are Located on Chromosome 2 at Bands q33-q34", Immunogenetics 31:198-201 (1990).
Lambrigts, D., Sachs, D. H., and Cooper. D. K. C. ( 1998) Discordant organ xenotransplantation in primates. Transplantation 66, 547-561 Larsen. C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C.
Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Wino, T. C.
Pearson. 1996.
Long -terrn acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.
Nature 381:434.
Larsen, R. D., Ri _ra-mlarrero, C. A., Emst, L. K., Cummings, _ D., and Lowe, J. B.
(1990) Frameshift and non sense mutations in a human genomic sequence homologous to a murine UDP- GaI:B-D-Gal 1,4-D-GIcNAccd,3-galactosyl transferase eDNA. J BioL
Chem.
265, 7055-7061 Ledbetter et al., "CD28 Ligation in T-Cell Activation: Evidence for Two Signal Transduction Pathways", Blood 75:1531-1539 (1990).
Ledbetter et al., "Crosslinking of Surface Antigens Causes Mobilization of Intracellular Ionized Calcium in T Lymphocytes", Proc. Natl. Acad. Sci. 84:1384-1388 (1987).
Lehto, T. et al. ( 1993) "Interactions of soluble CD59 with the terminal complement complexes"
J. Immunol. 151 (9 ):494 I -4949.
Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G.
Gibson. P. S.
Linsley, J. A. Bluestone. 1992. Long-terrn survival of xenogeneic pancreatic islet ~afts induced by CTLA4Ig. Sci 257:789.
Lesslauer et al., "T90/44 (9.3 Antigen), A Cell Surface Molecule with a Function in Human T
Cell Activation", Eur. J. Immunol. 16:1289-1296 (1986).
Leventhal, J. R.. Dahnasso, A. P., Cromwell, J. W.. Platt. J. L.. Manivel. C.
J.. Bolman 1 11, R. M., and Matas, A. J. ( 1993) Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55, 857-866 Leventhal, J. R., John, R., Fryer, J. P., Witson. J. C., Derlich, J. -M..
Remiszewski, J., Dalmasso. A. P., Matas, A. J.. Bolman 1 11. R. M. ( 1995) Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoabsotption.
Transplantation ~9, Leventhal, J. R., Sakiyalak, P., Witson, J., Simone, P., Matas, A. J., Bohnan.
R. M., and Dalmasso, A. P. ( 1994) The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 57,974-978 Lin, S. S.. Weidner, B. C., Byme. G. W., Diamond, L. E.. Lawson. J. H., Hoopes, C. W..
Daniels, L. J., Dagget, C. W., Parker. W., Harland, R. C.. Davis, R. D., Bollinger, R. R., Logan, J. S., and Platt. J. L. ( 1998) The role of antibodies in acute vascular resection of pigto-baboon cardiac transplants. J Clin. Invest. 101, 1745-1756 Lindsten. T.. K. P. Lee, E. S. Harris. B. Petryniak, N. Craighead. P. J.
Reynolds. D. B.
Lombard, G.J. Freeman. L. M. Nadler, G. S. Gray, C. B. Thompson. C. H. June.
1993. J.
hnmunol. 151:3489.
Linsley et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation", J. Exp. Med. 173:721-730 ( 1991 ).
Linsley et al., "T-Cell Antigen CD28 Mediates Adhesion with B Cells by Interacting with Activation Antigen B7BB-1", Proc. Natl. Acad. Sci. USA, 87:5031-5035 (1990).y Lu, C. Y., Khair-El-Din, T., Dawidson, I. A., Butler, T. M., Brasky, K. M., Vazquez, M.
A., Sicher, S. C. (1994). Xenotransplantation. FASEB J 8, 1122-1130 Lublin, et al., "Decay-accelerating factor: Biochemistry, molecular biology, and function,"
Ann. Rev. Immunol., 7:35-38, 1989.
Lublin, et al., "Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP)," J. Exp. Med., I 68:181- I 94, I 988.
Lublin, et al., "Phospholipid-anchored and Transmembrane Versions of Either Decay-accelerating Factor or Membrane Cofactor Protein Show Equal Efficiency in Protection from Complement-mediated cell Damage," J. Exp. Med., 174:35-44, 1991.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Marengere, Wate. ruse, Duncan, Mittrucker. Feng, T. Mak. 199f.. .cience 272:1170.
Matsumoto, L, and Osawa, T. (1969) Purification and characterization of an antiH(O) phytohemagglutinin of Ulex europeus. Biochim. Bioplays. Acta 194,180-189 McCurry, K. R., Kooyman, D. L., Alvarado, C. G., Cotterel, A. H., Martin, M.
J., Logan, J. S., and Plaft, J. L. (1995) Human complement regulatory proteins protect swine-to primate cardiac xenografts from humoral injury. Nat. Med. 7, 423-427 Meri, et al., 1990. "Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers" Immunology 71:1-9.
Miller, A.D., Buttimore, C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Molecular and Cellular Biology 6:2895-2902, 1986.
Miyagawa, S., Shirakura, R., lwata, K., Nakata, S., Matsumiya, G., Izutani.
H., Matsuda, H., Terado, A., Matsumoto, M., Nagasawa, S., and Seya, T. (1994) Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAF hybrid, on complementmediated swine endothelial cell lysis. Transplantation 58, 834-840 Moran, et al., 1992. "Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo," J. Immunol. 149:1736-1743.
Morganstern, J.P., Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper free packaging cell line.
1990. Nucleic Acid Research. 18:3587.
Norris, et al., 1993. "Structure-Function Relationships of CD59," Blood, 82 (Suppl.):202a.
O'Hair, D. P., McManus, R. P., Komorowski, R. (1994) Inhibition of chronic rejection in primate cardiac xenografts using mycophenolate mofetil. Ann. Thorac. Surg. 58, Okada, et al., 1989. "Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement" J. Immunol. 143:2262-2266.
P. M. Wallace, J. S. Johnson, J. F. MacMaster, K. A. Kennedy, P. Gladstone. P.
S. Linsley.
1994. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocomatibility complex barriers. Transpl. 58:602. (ms is better on ms than hu CTLA41 g) P. S. Linsley, W. Brady, M. Umes, L. S. Grosmaire, N. K. Dainle, J. A.
Ledbetter. 1991.
Pearson, T. C., D. Z. Alexander, K. J. Winn, P. S. Linsley, R. P. Lowry, C. P.
Larsen.
1994. Transplantation tolerance induced by CTLA4-1 a. Transpl. 57:1701.
Perkins et al., 1988. "A Study of the Structure of Human Complement Component Factor H
by Fourier Transform Infared Spectroscopy and Secondary Structure Averaging Methods,"
Biochemistry, 27:4004-4012.
Petranka, et al., 1993. "The Structure and Function of CD59: The Importance of the Disulfide Structure and Identification of a Primary Epitope," Molec. Immunol. 30 (suppl.
1):44.
Philbrick, et al., 1990. "The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility" Eur. J. Immunol. 20:87-92.
Platt, J. L., and Bach, F. H. (1991) Discordant xenografting: challenges and controversies.
Curr. Opin. Immun. 3, 735-739 Pruitt, S. K., Kirk, A. D., Bollinger, R. R.. Marsh, H. C. Jr., Collins, B.
H., Levin, J. L., Mault, J. R., Heinle, J. S., Ibrahim, S., Rudolph, A. R., Baldwin 111, W. M., and Sanfilippo, F. (1994) The effect of soluble complement receptor type I on hyperacute rejection of porcine xenografts. Transplantation 57, 363-370 R. H. Schwartz. 1989. Clonal expansion vs. functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev.
Immunol. 7:445. (Signal two)**
R. H. Schwartz. 1~,~. C:ostimulation of T lymphocytes: The role o, ~D28. CTLA-4, and B7BB I in interleukin-2 production and immunotherapy. Cell 71:1065. (rev) Rollins, et al., 1990. "The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9" J. Immunol. 144:3478-3483.
Rollins, et al., 1991, "Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9" J. Immunol. 146:2345-2351.
Ross, S. C., and Densen, P. (1984) Complement deficiency states and infection:
epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency. Medicine 63, 243-273 Rother, et al.. 1994. "Inhibition of Complement-Mediated Cytolysis by the Terminal Complement Inhibitor of Herpesvirus Saimiri," J. Virol. 68:730-737.
S. A. Rollins, S. P. Kennedy, A. J. Chodera, E. A. Elliott. G. B. Zavoico, L.
A. Matis.
1994. Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2.
Transp1.57:1709.
S. E. Maher, K. KarTnann, W. Min, C. C. W. Hughes, J. S. Pober, A. L. M.
Bothwell.
1996. Porcine endothelial CD86 is a major costimulator of xenogeneic human T
cells. J.
Immunol. 157:3838.
Saadi, S., and Platt, J. L. ( 1995) Transient perturbations of endothelial integrity induced by natural antibodies and complement. J Exp. Med. 181. 21-31 Sambrook, J., Fritsch, E.F., and T. Maniatis. 1989. Molecular Cloning: A
laboratory manual.
2"a edition. Cold Spring Harbor Press.
Sandrin, M. S. (1997) Down-regulation of Galcc(1,3)Gal expression by alpha l,2fucosyltransferase. Further characterization of alpha I?-fucosyltransferase transgenic mice.
Transplantation 64, 495-500 Sandrin, M. S., Fodor, W. L., Mouhtouris. E., Osman, N., Cohney, S., Rollins, S. A., Guilmette, E. R., Setter, E., Squinto, S. P., and McKenzie, 1. F. C. ( 1995) Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med. l, 1261-1267 Sandrin. M. S., Vaughan, H. A.. Dabkowski. P. L., and McKenzie, 1. F. C. ( 1993) Anti-pig IgM antibodies in human serum reacts predominantly with Gal((XI,3)Gal epitopes. Proc. Natl.
Acad. Sci. USA 90,11391-11395 Sawada, et al., 1990. "Isolation and expression of the full-length cDNA
encoding CD59 antigen of human lymphocytes" DNA and Cell. Biol. 9: 213-220.
Schaapherder, A. F. M., Daha, M. R., Te Bulte, M. -T. J. W., Van der Woude, F.
J., and Gooszen, H. G. ( 1994) Antibody-dependant cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation 57, 1376-1382 Schwartz, "A Cell Culture Model for T Lymphocyte Clonal Anergy", Science 248:1349-1356 ( 1990).
Sharma, A., Okabe, J., Birch, P., McClellan, S. B., Martin, M. J., Platt. J.
L., and Logan, J.
S. (1996) Reduction in the level of Galcc(1,3)Gal in transgenic mice and pigs by expression of an (x(1,2)fucosyltransferase. Proc. NatL Acad. Sci. USA 93, 7190-7195 Sommerville, C. A., and D'Apice, A. J. F. (1993) Future directions in transplantation:
xenotransplantation. Kidney International 44, Suppl. 42, S I 12-S 121 Southern. E. M. ( 1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J MoL BioL 98, 503-517 Stefanova, et al., 1~a9. "Characterization of a broadly expressed hm.'an leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol" Mol.
Immunol. 26:153-161.
Storb and Thomas, "Graft-Versus-Host Disease in Dog and Man: The Seattle Experience", Immunol. Rev. 88:215-238 ( 1985).
Su, et al., 1991. "The Glycosyl Phosphatidylinositol Anchor Is Critical for Ly-6A/E-mediated T Cell Activation," J. Cell Biol. 112:377-384.
Sun, H. V. Subbotin, C. Chen, A. Aitouche, L. A. Valdivia, M. H. Sayegh, P. S.
Linsley, J.
J. Fung, T. E. Starzl, A. S. Rao. 1997. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody.
Transpl. 64:1838.
Thompson et al., "CD28 Activation Pathway Regulates the Production of Multiple T-Cell-Derived Lymphokines/Cytokines", Proc. Natl. Acad. Sci. 86:1333-1337 (1989).
Tone, et al., 1992. "Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation" J. Mol. Biol. 227:971-976.
Tran, H. M., P. W. Nicherson. A. C. Restifo, M. A. Ivis-Woodward, A. Patel, R.
D. Allen.
T. B. Strom, P. J. O'Connell. 1997. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-fc treatment. J. Immunol. 159:2232.
Vanhove, B., deMartin, R., Lipp, J., and Bach, F. H. (1994) Human xenoreactive natural antibodies of IgM isotype activate pig endothelial cells. Xenotransplantation l, 17-22 Venneker, et al., 1992. "CD59: a molecule involved in antigen presentation as well as downregulation of membrane attack complex" Exp. Clin. Immunogenet. 9:33-47.
W. L. Fodor, S. A. Rollins, E. R. Guilmette, E. Setter, S. P. Squinto. 1995. A
novel bifimctional chimeric complement inhibitor that regulates C3 convertase and fon-nation of the membrane attack complex. J. Immunol 155:4135.
W. Steurer, P. W. Nickerson, S. W. Steele, J. Steiger. X. X. Zheng T. B. Strom 1995. Ex vivo coating of Islet cell allografts with murine CTLA4/fc promotes graft tolerance. J.
Immunol. 155:1165.
Walsh, et al., 1991. "Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement" Eur. J. Immunol. 21:847-850.
Walunas, T. L., D. J. Lenschow, C. Y. Bakker. P. S. Linsley, G. J. Freeman. J.
M. Green.
C. B. Thompson, J. A. Bluestone. 1994. CTLA-4 can ftinction as a negative regulator of T
cell activation. Immunity 1:405.
Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian. K. P.
Lee, C. B.
Thompson, H. Griesser, T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Sci 270:985.
Weaver and Unanue, "The Costimulatory Function of Antigen-Presenting Cells", Immunol.
Today 11:49-55 ( 1990).
Weiss, "Structure and Function of the T Cell Antigen Receptor", J. Clin.
Invest. 86:1015-1022 ( 1990).
Whitlow, et al., 1990. "H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement" Cell. Immunol. 126:176-184.
Wing, et al., 1992. "Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59"
Immunology 76:140-145.
Wm. Paul. 1998. Fundamental Immunology. Fourth Edition WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Yokochi et al., "B L~mpnoblast Antigen (BB-1) Expressed on Epstv__'-Barr Virus-Activated B
Cells Blasts, B Lymphoblastoid Cell Lines, and Burkitt's Lv_ mphomas", J.
Immunol.
128:823:827 (1981).
Zhao, et al., 1991. "Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement"J. Bioi.
Chem. 266: 13418-13422.
It will be understood that various modifications may be made to the embodiments disclosed herein. For example, the CSb-9 inhibitory domain and/or the T Cell inhibitory domain may be modified by creating amino acid substitutions or nucleic acid mutations provided at least some complement regulatory activity and some T Cell inhibitory activity remains after such modifications. Similarly, the nucleotide sequences of the chimeric protein protein may be modified by creating nucleic acid mutations which do not significantly change the encoded amino acid sequences, including third nucleotide changes in degenerate codons (and other "silent"
mutations that do not change the encoded amino acid sequence). Mutations which result in a highly conservative or silent amino acid substitution for an encoded amino acid while leaving the characteristics of the chimeric proteins essentially unchanged are also within the scope of disclosure. Also included are sequences comprising changes that are found as naturally occurring allelic variants of the genes for the T Cell inhibitory molecules and the CSb-9 inhibitory molecules used to create chimeric molecules described herein. All of the foregoing shall be considered as equivalents of the specific embodiments set forth herein. Therefore, the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. Those skilled in the an will envision other modifications within the scope of the claims appended hereto.
Removal of CC. FACS analysis was performed as described above in Figure 3 with the following exceptions. Drug resistant populations of porcine aortic endothelial cells (PAECs) transduced with pBABEhCTLA4-hCD59, or pBABEpCTLA4-hCD59 or pBABE vector alone were assayed for expression of CD59. Briefly, cells were incubated with l0ug/ml of either of the anti-CD59 antibodies, BRAlOG or MEM43 (Biodesign, Kennebunk, ME) , for 30 min., at 4C, in 0.1 ml of Dulbecco's PBS (DPBS) containing 1% Fetal Bovine Serum (FBS) or Bovine Serum Albumin (BSA). Cells were washed with DPBS before incubation with FITC conjugated antibodies to mouse IgG (Zymed, So.San Francisco, CA). In addition, an aliquot of the cell lines were treated with PI-PLC, (Boehringer Mannheim GmbH, Indianapolis, IN) at 1U/ml for lhour at 37C, prior to antibody incubations and FACS analysis on a Becton Dickenson FACSORT (Becton Dickenson, Franklin Lakes, NJ).
Fig. ~ depicts the results of cell killing experiments in which porcine aortic endothelia cells (PAECs) that express the chimeric molecules are protected from human serum-induced complement-mediated cell lysis. 5 x 10 3 vector control or hCTLA4hCD59 cells were seeded into the wells of a flat bottom 96 well plate 24 hours ahead of time. Adherent cells were washed twice using HESS containing 1% BSA.
Cells were sensitized by incubating with a polyclonal anti-PAEC antibody (Cocalico, Reamstown, PA), followed by incubation with the intracellular dye, Calcein AM(Molecular Probes, Eugene, OR) in HBSS/BSA for 30 minutes at 37°C. Excess Calcein AM was removed with two additional washes. Normal human serum complement source (Sigma, St. Louis, MO) was added to a final concentration of 10, 20, or 40% in 0.05m1 volume diluted in HBSS and incubated for 1 hour at 37°C. Supernatants containing released calcein from complement lysed cells was transferred to a fresh flat bottom microtiter plate.
The remaining intact cells with retained calcein were lysed using 0.05m1 1 °/a SDS. Released and retained fractions were read on a cytofluor 2350 (Millipore, Bedford, MA) at 485nm. Data is presented as percent cell death.
Fig. 6 depicts a FACS analysis that proves that the CTLA4 domain of the chimeric molecules interacts with B7 found on the same PAECs. Co-Stimulation Assays.
The costimulatory capacity of the PAEC was assayed using a modified endothelial cell costimulation assay (S. E. Maher, K. Karmann, W. Min, C. C. W. Hughes, J. S.
Pober, A. L. M. Bothwell. 1996. J. Immunol. 157:3838). 5 x 10 4 pBABE vector controI
(Vector) or hCTLA4hCD59 (CC) PAECs were seeded of a 96 well plates (Becton Dickenson, Franklin Lakes, NJ) 24 hours prior to co-culturing with T cells.
The following reagents were added to final concentrations of Sug/ml antiCD28, or antiB7.2;
l0ug/ml antiCTLA4; or Sug/well sCTLA4Ig. Prior to the costimulation assay, monolayers were washed gently with DPBS three times, followed by the addition of 1 x 10 5 Jurkats or T
cells as responder cells in 0.09m1 of RPMI 1640 +FBS, and incubated for 30min at 37°C.
Phytohemagglutinin (PHA) was added in a O.Olml volume to a final concentration of l0ug/ml for 20hrs at 37°C. Cell free supernatants were collected 20 hours post treatment and assayed by ELISA (R&D Systems, Minneapolis, MN). Plates were read on a Microplate Reader 350 (Biorad, Hercules, CA) at 485nm. Jurkat supernatents were tested undiluted.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Fig. 7 depicts the human amino acid sequence of DAF.
Detailed Description It has been found that functional domains capable of regulating the humoral effector functions of the immune system including complement inhibitory domains, such as a CSb-9 inhibitory domains or C3 inhibitory domains, and functional domains capable of regulating the cellular effector functions of the immune system, including T Cell inhibitory domains, can advantageously be combined to form a chimeric protein. The chimeric protein can be expressed on a porcine cell surface and can aid in the protection of the porcine cell, after xenotransplantation into a human, from both the human cellular immune response and human complement.
As used herein. the phrase "CSb-9 inhibitory activity" is used herein to describe the effects of CSb-9 inhibitor molecules of the foregoing types on the complement system and thus includes activities that lead to inhibition of the cell activating and/or lytic function of the membrane attack complex (MAC).
Suitable domains which exhibit CSb-9 inhibitory activity can include the entire amino acid sequence for a naturally occurring CSb-9 inhibitor protein or a portion thereof. For example, the CSb-9 sequence can be the mature CD59 molecule (i.e., amino acids I through 103 of Fig. 2E(2) ). Alternatively, the CSb-9 sequence can be a portion of a naturally occurring CSb-9 inhibitor protein, such as CD59. Active portions suitable for use herein can be identified using a variety of assays for CSb-9 inhibitory activity known in the art. See for example Rollins, et al.. J. Immunol.
144:3478. 1990; Rollins, et al., J. Immunol. 146:2345, 1991; Zhao, et al., J.
Biol. Chem. 266:
13418, 1991; and Rother, et al., J. Virol. 68:730, 1994. In general, the portion used should have at least about 25% and preferably at least about 50% of the activity of the parent molecule.
Suitable C3 inhibitory domains include the entire amino acid sequence for a naturally occurring C3 inhibtor or a portion thereof, such as one or more SCRs of the C3 inhibitory domain.
For example, the C3 sequence can be the mature DAF molecule (factor H, membrane cofactor protein or complement recepor 1 ). Alternatively, the C3 inhibitory domain can be a portion of a naturally occurring C3 inhibitor protein. Following the procedures used to identify functional domains of DAF (Adams, et al., 1991. J. Immunol. 147:3005-3011), functional domains of other C3 inhibitors can be identified and used herein. In general, the portion used should have at least about 25% and preferably at least about 50% of the activity of the parent C3 inhibitory molecule.
Particularly useful portions of mature C3 inhibitor proteins include one or more of the mature molecule's SCRs. These SCRs are normally approximately 60 amino acids in length and have four conserved cysteine residues which form disulfide bonds, as well as conserved tryptophan, glycine, WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 and phenylalanine/tyrc, ..~e residues. In one embodiment the C3 inhib~. ~
domain includes SCRs 2 through 4 of DAF (i.e. amino acids 97 through 286 shown in figure 7).
Suitable domains which exhibits T Cell inhibitory activity can include either at least a portion of the amino acid sequence for naturally occurring porcine CTLA4 or at least a portion of the entire amino acid sequence for naturally occurring human CTLA4. For example, the amino acid sequence which exhibits T Cell inhibitory activity can be amino acids 38 to 162 of the porcine CTLA4 sequence shown in Fig. 2C(2) or amino acids 38 to 161 of the human CTLA4 sequence shown in Fig. 2D(2) In general, the portion used should have at least about 25% and preferably at least about SO% of the activity of the parent molecule.
The amino acid sequence having CSb-9 inhibitory activity and the amino acid secquence having T Ce(1 inhibitory activity do not have to be directly attached to one another. A linker sequence can separate these two sequences. The linker preferably comprises between about one and at least about 6 amino. Suitable linker sequences can include glycines.
Other amino acids, as well as combinations of amino acids, can be used in the linker region if desired. In one embodiment, amino acids 153 to 158 of Fig. 2A(2) (GGGGGG in pCC) are the linker sequence.
In another embodiment, amino acids 152 to 157 of Fig. 2B(2) (SASASA in hCC) are the linker sequence.
Another embodiment provides recombinant cDNA that encodes an exon of the human homologue of CTLA4 is inserted into the coding region of human CD59, bisecting CD59 between the leader peptide and the mature peptide post-translational processing site, see Fig. 2A( 1 ). A
further embodiment provides recombinant cDNA which that encodes an exon of the porcine homologue of CTLA4 is inserted into the coding region of human CD59, bisecting CD59 between the leader peptide and the mature peptide post-translational processing site, see Fig. 2B(1). In both embodiments, the cDNA may include a coding sequence for a GPI anchor linkage site corresponding to amino acid 210 of CC and amino acid 77 of native CD59, see Fig.'s 2A( 1 ) and 2B( 1 ).
Molecules comprising nucleotide sequences encoding the CTLA4 and CD59 or DAF
domains can be prepared using a variety of techniques known in the art. For example, the nucleotide sequences encoding the CTLA4 nucleotide # 112-483 and CD59 leader peptide region nucleotide 1-75 and mature peptide nucleotide 76-384 domains can be produced using PCR
generation and/or restriction digestion of cloned genes to generate fragments encoding amino acid sequences having T Cell and CSb-9 inhibitory activities. These fragments can be assembled using PCR fusion or enzymatic ligation of the restriction digestion products (Sambrook, et al., Molecular Cloning: A laboratory manual. 2"d edition. Cold Spring Harbor Press, 1989);
Ausubel et al.
Current Protocols in Molecular Biology. 1991 ). Alternatively, any or all of the nucleic acid fragments used to assemble the chimeric genes can be synthesized by chemical means. In another WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 embodiment. the nuclt _.de sequences encoding the CTLA4 and DA>~ ' .pains can be produced using PCR generation and/or restriction digestion of cloned genes to generate fragments encoding amino acid sequences having T Cell and C3 inhibitory activities. These fragments also can be assembled using PCR fusion or enzymatic ligation of the restriction digestion products (Sambrook.
et al., Molecular Cloning: A laboratory manual. 2"° edition. Cold Spring Harbor Press. 1989;
Ausubel et al., Current Protocols in Molecular Biology. 1991). Any or all of the nucleic acid fragments used to assemble these chimeric genes can be synthesized by chemical means as well.
In another embodiment, recombinant expression vectors which include nucleic acid fragments the chimeric protein are provided. The nucleic acid molecule coding for such a chimeric protein can be inserted into an appropriate expression vector, i.e., a vector that contains the necessary elements for the transcription and translation of the inserted protein-encoding sequence.
Suitable host vector systems include. but are not limited to, mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, retroviruses, etc.); mammalian cell systems transfected with plasmids; insect cell systems infected with virus (e.g., baculovirusl;
microorganisms such as yeast containing yeast expression vectors, or bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA (see. for example, Goeddel, 1990). Commonly used promoters and enhancers derived from Polyoma virus, Adenovirus. Simian Virus 40 (SV40), the Molony murine leukemia virus (MMLV), including the long terminal repeat (MMLV-LTR), and human cytomegalovirus (CMV), including the cytomegalovirus immediate-early gene 1 promoter and enhancer are suitable. Eukaryotic promotors-BetaActin (Ng et al.) & H2Kb (Fodor et al. PNAS
1994) In a preferred embodiment, the cDNA of interest is cloned into a retroviral vector that is subsequently transfected into a mouse cell line called a "packaging line." The manipulation of retroviral nucleic acids to construct retroviral vectors and packaging cells is accomplished using techniques known in the art. See for example Ausubel, et al.. 1992. Volume 1, Section III
(units 9.10.1-9.14.3); Sambrook, et al., Molecular Cloning: A laboratory manual. 2"d edition.
Cold Spring Harbor Press, 1989; Miller, et al., Molecular and Cellular Biology 6:2895. 1986;
Eglitis, et al., Biotechniques. 6:608-614. 1988; U.S. Pat. Nos. 4,650,764, 4,861,719, 4,980,289, 5,122,767, and 5,124,263: as well as PCT Patent Publications Nos.
WO 85/05629, WO 89/07150, WO 90/02797, WO 90/02806, WO 90/13641, WO 92/05266, WO 92/07943, WO
92/14829, and WO 93/14188. Typically, the retroviral vector contains a gene that allows for selection via resistance to drugs such as puromyacin. It also contains nucleic acid sequence that allows for random or directed integration of the vector into a eukaryotic genome. Drug resistant cell lines are selected. These cells will produce virus particles capable of infecting other cells lines.
Porcine aortic endothelia cells (PAECs) are infected with the viruses by a process called viral transduction. The transduced PAECs are selected for by drug resistance. Drug resistant cells WO 01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 contain integrated copy ~f the viral vector DNA. Once in the porcine ge,._~ne, vector sequences or sequences associated with the chimeric gene control the expression of the chimeric protein.
In particular, the retroviral vectors of the invention can be prepared and used as follows.
First, a retroviral vector containing nucleic acid encoding for the chimeric protein described herein above is constructed and packaged into non-infectious transducing viral particles (virions) using an amphotropic packaging system, preferably one suitable for use in gene therapy applications.
Examples of such packaging systems are found in, for example, Miller, et al., Molecular and Cellular Biology 6:2895, 1986; Markowitz, et al., J. Virol. 62:1120-1124.
1988; Cosset, et al., J.
Virol. 64:1070-1078. 1999. U.S. Pat. Nos. 4.650,764, 4,861,719. 4,980.289, 5,122.767, and 5,124,263, and PCT Patent Publications Nos. WO 85/05629. WO 89/07150. WO
90/02797, WO
90/02806, WO 90/13641, WO 92/05266, WO 92/07943, WO 92/14829, and WO 93/14188.
A
preferred packaging cell is the PA317 packaging cell line (ATCC CRL 9078.
Rockville, MD). The Qeneration of "producer cells" is accomplished by introducing retroviral vectors into the packaging cells. The producer cells generated by the foregoing procedures are used to produce the retroviral vector particles (virions). This is accomplished by culturing of the cells in a suitable growth medium. Preferably, the virions are harvested from the culture and administered to the target cells which are to be transduced. Examples of such retroviral vectors are found in, for example, Korman, et al., Proc. Natl. Acad. Sci. USA. 84:2150-2154. 1987: Morgenstern, et al.. Nucleic Acid Research 18:3587. 1990; U.S. Pat. Nos. 4,405,712. 4,980,289, and 5,112,767: and PCT
Patent Publications Nos. WO 85/05629, WO 90/02797, and WO 92/07943. A
preferred retroviral vector is the MMLV derived expression vector pLXSN (See Miller, et al., Biotechniques. 7:981 1989). DNA can be introduce into cells by any standard method of transfection such as polybrene, DEAF, calcium phosphate, lipofection. electroporation. (See Sambrook, et al., Molecular cloning:
a laboratory manual. Second Edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, N.Y. 1989 ) Engineered transgenic animals (for example, rodent, e.g., mouse, rat, capybara, and the like, lagomorph, e.g., rabbit, hare, and the like, ungulate, e.g., pig, cow, goat, sheep, and the like, etc.) that express the chimeric protein described herein on the surfaces of their cells are provided using any suitable techniques known in the art. These techniques include, but are not limited to, microinjection, e.g., of pronuclei, electroporation of ova or zygotes, nuclear transplantation, and/or the stable transfection or transduction of embryonic stem cells derived from the animal of choice.
A common element of these techniques involves the preparation of a transgene transcription unit. Such a unit includes a DNA molecule which generally includes: 1 ) a promoter, 2) the nucleic acid sequence, and 3) a polyadenylation signal sequence. Other sequences, such as, enhancer and intron sequences, can optionally be included. The unit can be conveniently prepared by isolating a restriction fragment of a plasmid vector which expresses the CTLA4-CD59 protein in, for 6 ~ 02361646 2001-07-30 pCT~S00/29151 example, mammalian . .s. rreferably. the restriction fragment is free o.
acterially derived sequences that are known to have deleterious effects on embryo viability and gene expression.
The most well known method for making transgenic animals is that used to produce transgenic mice by superovulation of a donor female, surgical removal of the egg, injection of the transgene transcription unit into the pro-nuclei of the embryo, and introduction of the transgenic embryo into the reproductive tract of a pseudopregnant host mother, usually of the same species.
See for example U.S. Pat. No. 4,873,191, Brinster. et al.. 1985. Proc. Natl.
Acad. Sci. USA.
82:4438-4442.. Hogan, et al., in "Manipulating the Mouse Embryo: A Laboratory Manual". Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1986. , Robertson. 1987.
in Robertson.
ed. "Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRI.
Press, Eynsham.
Oxford, England, Pedersen, et al., 1990. "Transgenic Techniques in Mice--A
Video Guide", Cold Spring Harbor Laboratory, Cold Spring Harbor. N.Y.
The use of this method to make transgenic livestock is also widely practiced by those of skill in the art. As an example, transgenic swine are routinely produced by the microinjection of a transgene transcription unit into pig embryos. See, for example, PCT
Publication No.
W092/11757. In brief, this procedure may, for example, be performed as follows. First, the transgene transcription unit is gel isolated and extensively purified through, for example, an ELUTIP column (Schleicher & Schuell, Keene, N.H.), dialyzed against pyrogen free injection buffer ( 10 mM Tris, pH 7.4+0.1 mM EDTA in pyrogen free water) and used for embryo injection.
Embryos are recovered from the oviduct of a hormonally synchronized, ovulation induced sow, preferably at the pronuclear stage. They are placed into a 1.5 ml microfuge tube containing approximately 0.5 ml of embryo transfer media (phosphate buffered saline with 10% fetal calf serum). These are centrifuged for 12 minutes at 16.OOO×g in a microcentrifuge. Embryos are removed from the microfuge tube with a drawn and polished Pasteur pipette and placed into a 35 mm petri dish for examination. If the cytoplasm is still opaque with lipid such that the pronuclei are not clearly visible, the embryos are centrifuged again for an additional 1 S
minutes. Embryos to be microinjected are placed into a drop of media (approximately 100 µl) in the center of the lid of a 100 mm petri dish. Silicone oil is used to cover this drop and to fill the lid to prevent the medium from evaporating. The petri dish lid containing the embryos is set onto an inverted microscope equipped with both a heated stage (37.S°-38° C.) and Hoffman modulation contrast optics (200× final magnification). A finely drawn and polished micropipette is used to stabilize the embryos while about 1-2 picoliters of injection buffer containing approximately 200-500 copies of the purified transgene transcription unit is delivered into the nucleus, preferably the male pronucleus, with another finely drawn and polished micropipette. Embryos surviving the microinjection process as judged by morphological observation are loaded into a polypropylene tube (2 mm m) for transfer into the recipient pseudopregnant sow. Offspring are tested for the WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 presence of the transgt by Isolating genomic DNA from tissue remov. :rom the tail of each piglet and subjecting about ~ micrograms of this genomic DNA to nucleic acid hybridization analysis with a transgene specific probe. In a preferred embodiment, transgenic animals are produced according to the methods disclosed in PCT Publicaton No. WO/9907829, the contents of which are incorporated herein by reference.
Another commonly used technique for generating transgenic animals involves the genetic manipulation of embryonic stem cells (ES cells) as described in PCT Patent Publication No. WO
93/02188 and Robertson, in Robertson. ed. "Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press, Eynsham, Oxford, England 1987. In accordance with this technique, ES cells are grown as described in, for example, Robertson. in Robertson. ed.
"Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press, Eynsham.
Oxford, England; 1987, and in U.S. Pat. No. 5,166,06 to Williams et al.
Genetic material is introduced into the embryonic stem cells by, for example, electroporation according, for example, to the method of McMahon, et al., Cell. 62:1073; 1990, or by transduction with a retroviral vector according, for example, to the method of Robertson, et al., Nature. 323:445;
1986, or by any of the various techniques described by in Robertson. ed. "Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press, Eynsham, Oxford, England, 1987.
Chimeric animals are generated as described, for example, in Bradley, in Robertson. ed.
"Teratocarcinomas and Embryonic Stem Cells a Practical Approach" IRL Press. Eynsham, Oxford.
England. 1987.
Brietly, genetically modified ES cells are introduced into blastocysts and the modified blastocysts are then implanted in pseudo-pregnant female animals. Chimeras are selected from the offspring, for example by the observation of mosaic coat coloration resulting from differences in the strain used to prepare the ES cells and the strain used to prepare the blastocysts, and are bred to produce non-chimeric transgenic animals.
Other methods for the production of transgenic animals are disclosed in U.S.
Pat. No. 5,032,407 and PCT Publication No. W090/08832.
In order that those skilled in the art may be better able to practice the compositions and methods described herein, the following examples are given an illustration of the preparation of chimeric proteins having both complement inhibitory domains and T Cell inhibitory domains, as well as their ability to be expressed on a cell surface of an antigen presenting cell, bind targets on the same antigen presenting cell, and exhibit T Cell inhibitory activity. It is to be understood that commercially available reagents and/or instrumentation referred to in the examples were used according to the manufacturer's instructions unless otherwise indicated.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Example I
Construction of human CTLA4-human CD59 chimeric molecules A full length human CTLA4 cDNA was isolated from human peripheral blood leukocytes (PBLs) that were activated with 3ng/ml phorbol 12 myristate 13 acetate (PMA) and 0.4ug/ml ionomycin (commercially available from Sigma, St. Louis. MO). First strand cDNA synthesized from PBL RNA using reverse transcriptase as recommended by the vendor(Seikagaku America, Inc., Rockville, MD) was used as a template in a polymerase chain reaction (PCR) to amplify the extracellular domain encoded by exon 2 (according to methods desrcibed in Brunet, et al, "A
Differential Molecular Biology Search for Genes Preferentially Expressed in Functional T
Lymphocytes: The CTLA Genes". Immunol. Rev. 103:? I-36 ( 1988), and Dariavach, et al, ''Human Ig Superfamily CTLA-4 Gene: Chromosomal Localization and Identity of Protein Sequence Between Murine and Human CTLA-4 Cytoplasmic Domains." Eur. J.
Immunol.
18:1901-1905 (1988).). The 5' forward oligonucleotide:
~'GCCTGCAGATGCACGTGGCC3' and the 3' reverse oligonucleotide;
5'GGCTGCAGGGAGGCGGAGGCGGAGGCGTCAGAATCTGG3', which contained homologous nucleotides and nucleotide encoding linker sequence, were used in the following PCR reaction mixture to amplify a 406 base pair CTLA4 DNA fragment. Five microliters of a first strand synthesis of cDNA made from activated PBLs was amplified in the presence of l OmM
magnesium chloride, SOOmM dNTPs, 2uM oligonucleotides, 2.5 Units Taq polymerase (Perkin Elmer, Norwalk, CT) for forty cycles. Each cycle consisted of denaturing for one minute at 95°C, annealing at 55°C for one minute, and polymerizing at ?2"C for one minute. One cycle of polymerization at 72°C for ten minutes insured the addition of thymidine overhang for TA cloning.
The CTLA4 exon 2 fragment was ligated into the pCRII.ITOPO vector using the TOPO TA
cloning kit (commercially available from lnvitrogen, Carlsbad, CA) and used to transform the TOP
strain of E.Coli (commercially available from Invitrogen, Carlsbad. CA).
Plasmids containing the appropriately sized fragment were isolated and the inserts were subjected to DNA sequencing to confirm the integrity and identity of the DNA ( Wm. Keck Foundation Biotechnology Resource Laboratory Yale University, New Haven, CT). Plasmids that contained the verified CTLA4 exon 2 insert were digested with Pstl and the 406bp CTLA4 exon 2 fragment was isolated. A GEM7Z
plasmid (commercially available from Clontech, Palo Alto, CA) that contained the human CD59 sequence (gift from Dr. A. Bothwell, Yale University) that has a unique PstI
site located between the human CD59 signal sequence and mature protein coding sequence was digested with PstI. The PstI fragment that contained CTLA4 exon 2 was ligated into the corresponding PstI site on GEM7Z and plasmids that contained the correct insert were selected.
A BamHI-EcoRI fragment containing the entire chimeric human CTLA-human CD59 (hCTLA4hCD59) gene was excised from the plasmid and then subcloned into the amphitropic retroviral expression vector pBABEpuro (Morganstem, et all to generate the expression vector hCTLA4hCD59BABEpuro.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Example II
Cloning of porcine CTLA4 Porcine cDNA was prepared from porcine PBLs that were activated with 3ng/ml PMA and 0.4ug/ml ionomycin (commercially available from Sigma, St. Louis. MO). The cDNA was used as a template in a PCR using redundant primers designed from a comparison of human t Genbank accession # NM005214), mouse (X05719), rabbit (D49844), and bovine (X93305) nucleotide sequences. The 5' foreward oligonucleotide:
5'CCCMYMAGCCATGGCTYYYGG3' together with the 3' reverse oligonucleotide:
~'CCTCARTTRATRGGA4AAAATAAGGTG3' were used in PCR conditions as described in Example I, except annealing occurred at 4~C, and twenty cycles of amplification were used.
The PCR produced a 672 base pair fragment that was cloned into the TOPO vector using the TOPO
TA cloning kit (commercially available from Invitrogen, Carlsbad, CA1. DNA
Sequence analysis confirmed that the insert was the full-length porcine CTLA~ clone.
Example III
Construction of porcine CTLA4-human CD59 chimeric molecules The extracellular domain of porcine CTLA4 encoded by exon 2 was PCR
amplified from the TOPO plasmid prepared in Example II using a 5' foreward oligonucleotide:
5'CCATGCATAT GCACGTGGCC CAGCCTGCAG, and a 3' oligonucleotide: 5'CATGCATGCC ACCGCCACC GCCACCGAAA TCAGAATCTG
GGCATGGTTC TGGATCAATG3' that contained homologous pCTLA4 sequence restriction sites and linker sequence using the same PCR conditions as described in Example I, except that only 35 cycles of amplification were used to generate a 393 base pair DNA
fragment. The fragment was cloned into the TOPO vector using the TOPO TA cloning kit (commercially available from Invitrogen, Carlsbad, CA). DNA sequence analysis confirmed that the insert was the porcine CTLA4 exon 2. The plasmid was digested with Nsi I and the fragment that contained the CTLA4 exon 2 was isolated and ligated into the PstI site of the GEM7Z plasmid that contained human CD59 as described in Example I. The BamEl-EcoRl fragment containing the chimeric pig CTLA~-human CD59 molecule (pCTLA4hCD59) was excised from the plasmid and then subcloned into the amphitropic retroviral expression vector pBABEpuro (See Morgenstern, et al., Nucleic Acids Res. 18:3587 1990.) to generate the expression vector pCTLA4hCD59BABEpuro.
Example IV
Cell surface expression of hCTLA4-hCD59 chimeric molecules To create a cell line that expresses the human CTLA4-humanCD59 chimeric molecule a cell line must be created that produces retroviral vectors that contain the necessary gene. Another cell line must then be transduced with the virus to create a population of cells that express the protein.
To produce the retrovirus, the murine amphitropic packaging cell line PA317 (ATCC, Rochville, MD) was transfected with the expression vector prepared in Example I
(hCTLA4hCD59BABEpurol , example 3 or BABEpuro (vector control DNA) by the polybrene method (See Sambrook, et al., Molecular cloning: a laboratory manual. Second Edition. Cold Spring Harbor Labora..,ry Press, Cold Spring Harbor, N.Y. 1989.) Te,, micrograms of DNA
were added to PA317 cells in ~ml of Dulbecco minimum essential medium (DMEM) .
available from Cellgro, Herndon. VA. containing 10% heat inactivated fetal bovine serum (FBSI followed by a five hour treatment with 30mg/ml polybrene (Sigma. St.Louis. MO) , without a dimethylsufoxide (DMSO) shock. The cells were washed and incubated in DMEM
with 10% FBS
and 48 hours post transfection, the cells were treated with 3mg/ml puromycin to select drug resistant transfectants. The transfected PA317 cells produced retrovirus and viral supernatents which were harvested as described by Morgenstern, et al. Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper free packaging cell line. 1990. Nucleic Acid Research. 18:3587. The next step was to transduce porcine cells to create a porcine cell line that expresses human CTLA4-humanCD59 protein and the porcine CTLA4-hCD59. Using standard methods 5 x 105 porcine aortic endothelial cells (PAEC) were transduced using 1.5 ml of viral supenatent added to 3.~ ml of DMEM with 10% FBS followed by the addition of polybrene to 8 mg/ml for 5 hours. Following transduction the cells were incubated in DMEM with 10% FBS for 48 hours. The cells were split into selection medium (DMEM with 10% FBS and 3ug/ml puromycin). Puromycin resistent cell populations that express human CTLA4-human CD59 chimeric molecules were identified by florescence activated cell sorting (FACS) analysis using antibodies to human CTLA4 and human CD59 using standard methodologies (Current Protocols in Immunology, ed. J. E.
Coligan, et al).
Populations of PAEC transduced with hCTLA4hCD59BABEpuro, pCTLA4hCD59 or BABEpuro vector alone were assayed for cell surface expression of CD59 and CTLA4 by FACS analysis using antibodies to human CTLA4 and human CD59. Briefly, cells were incubated with l Omg/ml anti CTLA4 (commercially available from Ancell. Bayport. NIN) for 30 min., at 4°C. in 0. I ml of Dulbecco's phosphate buffered saline (DPBS) containing 1 % FBS or bovine serum albumin (BSA). Cells were washed with DPBS before incubation with FITC conjugated antibodies to mouse IgG (commercially available from Zymed, Co., San Francisco, CA). FACS
analysis was carried out on a Becton Dickenson FACSORT (Becton Dickenson, Franklin Lakes, NJ) instrument using standard methodologies ( Current Protocols in Immunology, Ed.
J.E.Coligan). The pBABEpuro transduced cells were negative for hCTLA4 expression (Figure 3). The hCTLA4hCD59 PAECs exhibited high level expression of hCTLA4 and hCD59 as determined by FACS analysis with antibodies specific to each moiety (Fig. 3 and Fig. 4).
The hCTLA4hCD59 cell line was also treated with PI-PLC and then assayed for expression of the chimeric molecule to further demonstrate that the chimeric molecules were anchored to the cell surface with a CD59 GPI anchor linkage, by enzymatically cleaving the CD59 GPI membrane attachment. Figure 4 illustrates the loss of cell surface expression following PIPLC treatment, as indicated by reduced antibody reactivity following enzymatic digestion.
Example V
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Cell surface expression. ~i pL rLA4-hCD59 chimeric molecules Production of a PAEC line to express pCTLA4hCD59 was carried out in the same manner as described in Example IV, however the DNA used to transfect the virus producing cell line was the expression vector pCTLA4hCD59BABEpuro prepared in Example III. FACS analysis for cell surface expression was carried out as described in Example IV. However, detection of the pCLTA4 had to be accomplished by a different method because the human specific anti CTLA4 antibody, ANC152.2, only bound to the human CTLA4 molecule and did not cross react to the pig molecule (data not shown). Therefore, the pCTLA4-hCD59 molecule was detected with the anti CD59 mAb, BRAIOG or MEM 43 (Biodesign, Kinnebunk. ME). Figure 4 illustrates expression on hCTLA4-hCD59 and pCTLA4-hCD59 transduced PAEC.
The pCTLA4hCD59 cell line was also treated with PI-PLC and then assayed for expression of the chimeric molecule to demonstrate that the chimeric molecules were anchored to the cell surface with a CD59 GPI anchor linkage by cleaving the CD59 GPI membrane attachment. Fig. 4 illustrates the loss of cell surface expression following PI-PLC treatment.
Both moieties could not be detected post digestion.
Example VI
Demonstration of human CD59 activity in the hCTLA4-hCD59 chimera To determine if the CD59 moiety was functional, complement-mediated killing assays were performed using normal human serum as a source of complement. PAECs (5 x 103) transduced with vector control or hCTLA4hCD59 were seeded into the wells of a flat bottom 96 well plates.
After 24 hours adherent cells were washed twice using Hanks balanced salt solution (HBSS) containing 1 % BSA (HBSS/BSA). Cells were sensitized by incubating with a polyclonal anti-PAEC antibody ( Cocalico, Reamstown, PA), followed by incubation with the intracellular dye, Calcein AM (commercially available from Molecular Probes, Eugene, OR) in HBSS/BSA for 30 minutes at 37°C. Excess Calcein AM was removed with two additional washes. Normal human serum (commercially available from Sigma, St. Louis, MO) was used as a complement source and was added to a final concentration of 10%, 20%, or 40% in O.OSmI volume diluted in HBSS and the cells were incubated for 1 hour at 37°C. Supernatants containing released calcein from complement lysed cells was transferred to fresh flat bottom microtiter plates.
The remaining intact cells with retained calcein were lysed using O.OSmI 1 % sodium dodecylphosphate (SDS). The optical density (OD) at 485 nm was determined for all samples using a cytofluor 2350 spectrophotometer (commercially available from Millipore, Bedford, MA). The percent cell death is determined by comparing the OD obtained from untreated cells to that obtained from treated cells. Figure 5 illustrates the percentage of cell death due to increasing concentrations of human WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 serum. Vector transdu,..;d P.yECs were susceptible to human serum in ~ .pose dependent manner.
However, hCTLA4hCD59 PAECs were 2-3 fold more resistant to human serum induced cell lysis at all concentrations of serum tested as compared to control PAECs.
Example VII
Demonstration of human CTLA4 activity in the hCTLA4-hCD59 chimera When antigen presenting cells (APC) such as PAECs are co-cultured with Jurkat cells, a human T-cell line ATCC TIB 152 or human T cells (responder cells) a costimulatory signal results that elicits interleukin 2 (IL-2) production from the responder cells.
Therefore, to test the function of the hCTLA4 molecule in the context of the chimeric molecule, costimulation assays were performed using Jurkat cells as responder cells and vector control, hCTLA4hCD59 PAECs or pCTLA4-CD59 as APCs, respectively. The costimulatory capacity of the various PAECs was assayed using a modified endothelial cell costimulation assay (as described in Maher. et al., Journal of Immunology, 157:3838 1999 ). PAECs transduced with pBABE vector control, hCTLA4hCD59, or pCTLA4-hCD59 were seeded at 5 x 104 cells per well in 96 well plates (commercially available from Becton Dickenson, Franklin Lakes, NJ) 24 hours prior to coculturing with T cells. The following reagents were added to final concentrations of Sug/ml for antiCD28, or antiB72(see for example); l0ug/ml antiCTLA4 (Ancell, Bayport, MN); or Sug/well sCTLA4Ig(Ancell, Bayport, MN). Prior to the costimulation assay, monolayers were washed gently with DPBS three times, followed by the addition of I x 105 Jurkats or T
cells as responder cells in 0.09m1 of (spell out RPMI) (RPMI 1640) with FBS, and incubated for 30min at 37°C
PHA, phytohemaglutinin (Sigma L7019) was added in a O.lml volume to a final concentration of lOmg/ml for 20hrs, at 37°C. Cell free supernatants were collected 20 hours post treatment and assayed for IL-2 by enzyme linked immunosorbant assay (ELISA) (commercially available from R&D Systems, Minneapolis, MN). Optical density (OD) at 485nm was determined using a Microplate Reader 3550 (commercially available from Biorad, Hercules, CA) and the OD is proportional to IL-2 production and determined by comparison to a calibration curve generated with known amounts of IL-2. Jurkat supenatents were tested undiluted.
IL-2 release from stimulated Jurkat cells is depicted in Figure 6. The amount of IL-2 elicited from Junket cells in the presence or absence of pig aortic endothelial cells as antigen presenting cells requires primary and secondary stimulatory signals. Without the secondary co-stimulatory signal provided by an APC or anti CD28, Jurkats remain unactivated, and secrete little to no IL2.
The assay utilizes the lectin, phytohemaglutinin (PHA) to cross-link the T
cell receptor complex and stimulate the primary signal. When both the primary and secondary signals are provided, 446pg/ml of IL-2 is secreted. If the secondary signal is provided by vector control PAEC as APC
instead of anti CD28, 406pg/ml IL-2 is secreted. An antibody to pig B7.2 blocks the secondary signal and therefore IL,-2 production by specifically binding to the B7.2 molecules on the APC
thereby blocking the co-stimulatory second signal. CTLA4 is an alternate ligand for B7.1 and WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 B7.2 and has a ten to twenty told higher binding affinity than CD28.
T~..,refore. using a soluble form of CTLA4, shCTLA4Ig binds to B7 on PAEC preventing binding of CD28 on Jurkats resulting in no secondary signal. If the secondary signal is provided by an APC bearing the hCTLA4-hCD59, a huge reduction is seen in the secretion of IL-2 to 69pg/ml, nearly to levels attained with anti pB7.2 or shCTLA4. CTLA4 in the chimeric molecule binds B7.2 in cis preventing Jurkats from CD28 engagement. A blocking antibody to hCTLA4 specifically binds the CTLA4 mioety of the hCTLA4-hCD59 molecule and prevents it from binding to pB7.2 on the CCPAEC surface. B7.2 is therefore available to bind CD28 on Jurkat cells leading to activation and IL-2 secretion. HCTLA4-hCD59 is a gpi linked molecule and. can be cleaved off the cell surface of the cells by phosphotidyl inositol phospholipase C. When hCTLA4-hCD59 is removed the secondary signal is restored, and the Junket cells become activated and secret IL-2.
REFERENCES
The following references are incorporated herein by reference to more fully describe the state of the art. All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
A. Aruffo, B. Seed. 1987. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. PNAS 84:8573. (cloning CD28) A. S. B. Edge, M. E. Gosse. J. Dinsmore. 1998. Xenogeneic cell therapy: cur-rent progress and future developments in porcine cell transplantation. Cell Transpl. 7:525.
Adams. et al., 1991. "Contribution of the Repeating Domains of Membrane Cofactor Protein (CD46) of the Complement System to Liaand Binding and Cofactor Activity"
Journal of Immunology 147:3005-301 1.
Albrecht, et al., 1992. "Herpesvirus Saimiri Has a Gene Specifying a Homologue of the Cellular Membrane Glycoprotein CD59" Virology 190:527-530.
Allen, "Antigen Processing at the Molecular Level", Immunol. Today 8:270-273 ( 1987).
Aruffo and Seed, "Molecular Cloning of a CD28 cDNA by a High-Efficiency COS
Cell Expression System", Proc. Natl. Acad. Sci. 84:8573-8577 (1987).
Auchincioss Jr., H., R. Lee, S. Shea, J. S. Markowitz, M. J. Grusby, L. H.
Glimcher. 1993.
The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class 11-deficient mice. PNAS 90:3373.
Auchincloss, H. ( 1988) Xenogeneic transplantation. A review. Transplantation 46,1-20.
Auchincloss, H. (1998) Xenogeneic transplantation. Annu. Rev. Immunol. 16.433-B.R. Blazar, P. A. Taylor, A. Panoskaltsis-Mortari. G. S. Gray, D. A. Vallera.
1995.
Coblockade of the LFAI:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex- disparate donor grafts. Blood. 9:2607.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Ausubel, F.M., B._.~t, tc., Kingston. R.E., Moore, D.D., Seidma._. J.G., Smith. J.A..
Struhl. K. eds., Current Protocols in Molecular Biology. 1991.
Bach. F. H., Turinan, M. A.. Vercelloti. G. M.. Platt. J. L.. and Dalmasso, A.
P. ( 1991 Accomodation: a working paradigm for progressing toward discordant xenografting.
Transplant. Proc. 23,205-208 Brunet et al., "A Differential Molecular Biology Search for Genes Preferentially Expressed in Functional T Lymphocytes: The CTLA Genes", Immunol. Rev. 103:21-36 ( 1988).
Brunet et al., "A New Member of the Immunoalobulin Superfamily-CTLA-s", Nature 328:267-270 ( 1987). ~ .
Byme, G. W., McCurry, K. R., Martin, M. J., McClellan. S. M.. Platt. J. L., and Logan, J.
S. ( 1997) Transgenic pigs expressing human CD59 and decay accelerating factor produce an intrinsic barrier to complement-mediated daTnage. Transplantation 63, 149-155 C. A. Bravery, P. Batten. M. H. Yacoub, M. L. Rose. 1995. Direct recognition of SLA- and HLA- like class 11 antigens on porcine endothelium by human T cells results in T cell activation and release of interleukin-2. Transpl. 60:1024.
C. B. Thompson. T. Lindsten. J. A. Ledbetter, S. L. Kunkel, H. A. Young S. G.
Emerson.
J. M. Leiden, C. H. June. 1989. CD28 activation pathway regulates the production of multiple T-cell- derived lymphokines/cytokines. PNAS 84:1333. (IL-2 secretion due to C. F. Morris. C. J. Simeonovic, M. Fung, J. D. Wilson, A. J. Hapel. 1995.
Intragraft expression of cytokine transcripts during pig proislet xenograft rejection and tolerance in mice.
J. Immunol. 154:2470. (CD4+T mediate xenorejectionl C. H. June. J. A. Ledbetter, P. S. Linsley, C. B. Thompson. 1990. Role of CD28 receptor in T cell activation. Immunol. Today 1 1:21 1.
Chahine, A. A., M. Yu, M. M. McKeman. C. Stoechert, H. T. Lau. 1995.
Immunomodulation of pancreatic islet allografts in mice with CTLA41 g secreting muscle cells.
Transpl. 59:1313.
Chen. C. G., Fisicaro, N., Shinkel, T. A., Aitken, V., Katerelos, M., van Denderen, B. J.
W., Tange, M. J., Crawford. R. J.. Robins. A. J., Pearse. M. J., and D'Apice.
A. J. F.
( 1996) Reduction in Gal- alpha 1.3-Gal epitope expression in transgenic mice expressing human Htransferase. Xenotransplantation 3. 69-75 Chen. C. G., Salvaris. E. J.. Romanella, M., Katerelos, M.. Fisicaro, N., Aminian, A., D'Apice, A. J. F., and A. J., Pearse. M. J. ( 1996) Trans~enic expression of human ocl,2fucosyltransferase (H- transferase) prolongs mouse heart survival in an ex vivo model of xenograft rejection. Transplantation 6~. 832-837 Clark et al., "Polypeptides on Human B Lymphocytes Associated with Cell Activation", Human Immunol. 16:100-113 (1986).
Cohney, S.. McKenzie, 1. F. C., Patton, K.. Prenzoska, J.. Ostenreid, K., Fodor, W. I
Costa, C., Zhao, L., DeCesare. S., and Fodor, W. L. Comparative analysis of three genetic modifications designed to inhibit human serum-mediated cv_ tolysis.
Xenotransplanration (in press).
Coligan, J.E.. Kruisbeek, A.M., Margulies. D.H., Shevach, E.M., Strober, W.
eds. 1992.
Current Protocols in Immunology. J.Wiley and Sons, NY.
Cowan" P. J., Chen, C. G., Shinkel, T. A.. Fisicaro, N., Salvaris, E., Aminian, A., Romanella, M., Pearse, M. J., and D'Apice. A. J. F. (1998) Knock-out of a1,3-galactosyltransferase or expression of ccl,2-fucosyltransferase further protects CD55- and CD59-expressing mouse hearts in an ex vivo model of xenograft rejection.
Transplantation 65.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Coyne et al., 199. Mapping of epitopes, glycosylation sites, and ~~~nplement regulatory domains in human decay accelerating factor," Journal of Immunology 149:2906-2913.
Cozzi, E. Yannoutsos, N., Langford, G. A., Pino-Chavez, G., Wallwork, and White, D. J.
G. (1997) Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs. In Xenotransplantation (Cooper. D. K.
C.and Kemp, E., eds) pp 665-682, Springer-Verlag, Berlin, Heidelberg Cramer, D. V. ( 1996) Natural antibodies. In Transplantation biology: cellular and molecular aspects. (Tilney, N. L., Strom, T. B., Paul, L. C., eds) pp 473-481, Raven Press, New York CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med.
174:561.
Dalmasso. A. P., Vercellotti, G. M., Platt. J. L., and Bach, F. H. ( 1991 ) Inhibition of complement- mediated endothelial cell cytotoxicity by decay-accelarating factor.
Tran.spLantation 52, 530-533 Dalmasso, A. P., Vercelotti. G. M., Fischel, R. J., Bolman, R. M. Bach. F. H., and Platt, J.
L. ( 1992) Mechanism of complement activation in the hyperacute rejection of porcine organs in primate recipients. Arn. JPathol. 140, 1157-1 166 Dalrnasso, A.P. et al. (1991) "Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor" Transplantation X2(3):530-533.
Damle et al., "Alloantigen-Specific Cytotoxic and Supressor T Lymphocytes are Derived from Phenotypically Distinct Precursors", J. Immunol. 131:2296-2300 ( 1983).
Damle et al., "Immunoregulatory T Lymphocytes in Man", J. Immunol. 139:1501-( 1987).
Damle et al., "Monoclonal Antibody Analysis of Human T Lymphocyte Subpopulations Exhibiting Autologous Mixed Lymphocyte Reaction", Proc. Natl. Acad. Sci.
78:5096-5098 (1981).
Dariavach et al., "Human Ig Superfamily CTLA-4 Gene: Chromosomal Localization and Identity of Protein Sequence Between Murine and Human CTLA-4 Cytoplasmic Domains."
Eur. J. Immunol. 18:1901-1905 (1988).
Davies. et al., 1989. "CD59, an LY-6-like protein expressed in human lymphoid cells.
regulates the action of the complement membrane attack complex on homologous cells" J. Exp.
Med. 170:637-654.
Davis, E. A., Pruitt, S. K., Greene, P. S., Ibrahim, S., Lam, T. T., Levin, J.
L., Baldwin I 11, W. M., Sanfilippo, F. ( 1996) Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts.
Transplantation 62. 10181023 Diamond, L. E., McCurry, K. R., Martin, M. J., McClellan, Oldham, E. R., Platt. J. L., and Logan, J. S. ( 1996) Characterization of transgenic pigs expressing fimctionally active human CD59 on cardiac endothelium. Transplantation 61, 1241-1249 Fodor, W. L., Williams, B. L., Matis, L. A., Madri, J. A., Rollins, S. A., Knight, J. W., Velander, W., and Squinto, S. P. (1994) Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc. Natl. Acad. Sci. USA 9I. I 1153-11157 Galili, U. ( 1993) Evolution and pathophysiology of the human anti-a-galactosyl IgG (antiGal) antibody. SpringerSemin. ImmunopathoL 15,155-171 Gallili U. ( 1997) Anti-agalactosyl (Anti-Gal) antibody damage beyond hyperacute rejection. In Xenotransplantation (Cooper, D. K. C.and Kemp, E.. eds) pp 95-103, Springer-Verlag, Berlin, Heidelberg Goodman, D. J., Millan, M. T., Ferran, C., and Bach, F. H. (1997) Mechanisms of delayed xenograft rejection. In Xenotransplantation (Cooper, D. K. C.and Kemp, E., eds) pp 95-103, Springer-Verlag, Berlin, Heidelberg WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 H. Auchincloss, J. , D. t-~. Sachs. 1998. Xenogeneic transplantatic,, . Ann.
Rev. Immunol.
I 6:433.
Hancock, W. W., M. H. Sayegh, X. Zheng, R. Peach. P. S. Linsley, L. A. Turka.
1996.
Costimulatory function and expression o CD40 ligand. CD80, and CD86 in vascularized murine cardiac allograft rejection. PNAS 93:13967.
Harper. K., C. Balzano. E. Rouvier, M. Mattei, M. Luciani. P. Golstein. 1991.
and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J.
hmmmol.
147:1037.
Hayes, C. E., and Goldstein, 1. J. (1974) An a-D-galactosyl-binding lectin from Bandeir-aea simplicifolia seeds. J BioL Chem. 249. 1904- I 914 Higgins, P.J.,Ko.J.L., Lobell.R., Sardonini,C., Alessi,M.K.. Yeh, C.G. 1997.
J.1. 158:
287281. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities.
Inverardi. L., Clissi, B., Stolzer. A. L.. Bender, J. R.. Sandrin. M. S., and Pardi. R. ( 1997) Human natural killer lymphocytes directly recognize evolutionary conserved oliQosaccharide ligands expressed by xenogeneic tissues. Transplantation 63. 1318-1330 J. A. Bluestone. 1997. Is CTLA-4 a master switch for peripheral T cell tolerance? J. Irnmunol.
158:1989.
June et al., "T-Cell Proliferation Involving the CD28 Pathway is Associated with Cyclosporine-Resistant Interleukin 2 Gene Expression", Mol. Cell. Biol. 7:4472-4481 ( 1987).
K. lwata, T. Seya, H. Arita, S. Nagasawa. 1994. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein. J. Immunol. 152:3436.
Kalli, K.R. et al. (1991) "Mapping of the C3b-binding Site of CRl and Constmction of a (CRl)2-F(ab')2 Chimeric Complement Inhibitor." J. Exp. Med. 174:1451-1460.
Kennedy, S. P., Rollins, S. A., Burton, W. V., Sims, P. J., Bothwell. A. L.
M., Squinto. S.
P., and Zavoico, G. B. ( 1994) Protection of porcine aortic endothelial cells ftom complementmediated cell lysis and activation by recombinant human CD59.
Transplantation 57, 14941501 Kohno et al., "CD28 Molecule as a Receptor-Like Function for Accessory Signals in Cell-Mediated Augmentation of IL-2 Production", Cell Immunol. 131:1-10 ( 1990).
Koike, C., Kannagi, R., Takuma, Y., Akutsu. F., Hayashi. S., Hiraiwa, N., Kadomatsu, T., Murainatsu, T., Yarnakawa, H., Nagai, T., Kobayashi. S., Okada, H., Nakashima, L, Uchida, K., Yokoyama, L, and Takagi, H. (1996) Introduction of cc(1,2)-fticosyltransferase and its effect on (x-Gal epitopes in transgenic pig. Xenotransplantation 3. 81-Kroshus, T. J., Bohnan I 11, R. M., Dalmasso, A. P., Rollins, S. A., Guilmette, E. R., Williarns, B. L., Squinto, S. P., and Fodor. W. L. ( 1996) Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perftision model.
Transplantation 61, 1513- 1521 Lafage-Pochitaloff et al., "Human CD28 and CTLA-4 Ig Superfamily Genes are Located on Chromosome 2 at Bands q33-q34", Immunogenetics 31:198-201 (1990).
Lambrigts, D., Sachs, D. H., and Cooper. D. K. C. ( 1998) Discordant organ xenotransplantation in primates. Transplantation 66, 547-561 Larsen. C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C.
Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, K. J. Wino, T. C.
Pearson. 1996.
Long -terrn acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.
Nature 381:434.
Larsen, R. D., Ri _ra-mlarrero, C. A., Emst, L. K., Cummings, _ D., and Lowe, J. B.
(1990) Frameshift and non sense mutations in a human genomic sequence homologous to a murine UDP- GaI:B-D-Gal 1,4-D-GIcNAccd,3-galactosyl transferase eDNA. J BioL
Chem.
265, 7055-7061 Ledbetter et al., "CD28 Ligation in T-Cell Activation: Evidence for Two Signal Transduction Pathways", Blood 75:1531-1539 (1990).
Ledbetter et al., "Crosslinking of Surface Antigens Causes Mobilization of Intracellular Ionized Calcium in T Lymphocytes", Proc. Natl. Acad. Sci. 84:1384-1388 (1987).
Lehto, T. et al. ( 1993) "Interactions of soluble CD59 with the terminal complement complexes"
J. Immunol. 151 (9 ):494 I -4949.
Lenschow, D. J., Y. Zeng, J. R. Thistlethwaite, A. Montag, W. Brady, M. G.
Gibson. P. S.
Linsley, J. A. Bluestone. 1992. Long-terrn survival of xenogeneic pancreatic islet ~afts induced by CTLA4Ig. Sci 257:789.
Lesslauer et al., "T90/44 (9.3 Antigen), A Cell Surface Molecule with a Function in Human T
Cell Activation", Eur. J. Immunol. 16:1289-1296 (1986).
Leventhal, J. R.. Dahnasso, A. P., Cromwell, J. W.. Platt. J. L.. Manivel. C.
J.. Bolman 1 11, R. M., and Matas, A. J. ( 1993) Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55, 857-866 Leventhal, J. R., John, R., Fryer, J. P., Witson. J. C., Derlich, J. -M..
Remiszewski, J., Dalmasso. A. P., Matas, A. J.. Bolman 1 11. R. M. ( 1995) Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoabsotption.
Transplantation ~9, Leventhal, J. R., Sakiyalak, P., Witson, J., Simone, P., Matas, A. J., Bohnan.
R. M., and Dalmasso, A. P. ( 1994) The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 57,974-978 Lin, S. S.. Weidner, B. C., Byme. G. W., Diamond, L. E.. Lawson. J. H., Hoopes, C. W..
Daniels, L. J., Dagget, C. W., Parker. W., Harland, R. C.. Davis, R. D., Bollinger, R. R., Logan, J. S., and Platt. J. L. ( 1998) The role of antibodies in acute vascular resection of pigto-baboon cardiac transplants. J Clin. Invest. 101, 1745-1756 Lindsten. T.. K. P. Lee, E. S. Harris. B. Petryniak, N. Craighead. P. J.
Reynolds. D. B.
Lombard, G.J. Freeman. L. M. Nadler, G. S. Gray, C. B. Thompson. C. H. June.
1993. J.
hnmunol. 151:3489.
Linsley et al., "Binding of the B Cell Activation Antigen B7 to CD28 Costimulates T Cell Proliferation and Interleukin 2 mRNA Accumulation", J. Exp. Med. 173:721-730 ( 1991 ).
Linsley et al., "T-Cell Antigen CD28 Mediates Adhesion with B Cells by Interacting with Activation Antigen B7BB-1", Proc. Natl. Acad. Sci. USA, 87:5031-5035 (1990).y Lu, C. Y., Khair-El-Din, T., Dawidson, I. A., Butler, T. M., Brasky, K. M., Vazquez, M.
A., Sicher, S. C. (1994). Xenotransplantation. FASEB J 8, 1122-1130 Lublin, et al., "Decay-accelerating factor: Biochemistry, molecular biology, and function,"
Ann. Rev. Immunol., 7:35-38, 1989.
Lublin, et al., "Molecular cloning and chromosomal localization of human membrane cofactor protein (MCP)," J. Exp. Med., I 68:181- I 94, I 988.
Lublin, et al., "Phospholipid-anchored and Transmembrane Versions of Either Decay-accelerating Factor or Membrane Cofactor Protein Show Equal Efficiency in Protection from Complement-mediated cell Damage," J. Exp. Med., 174:35-44, 1991.
WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Marengere, Wate. ruse, Duncan, Mittrucker. Feng, T. Mak. 199f.. .cience 272:1170.
Matsumoto, L, and Osawa, T. (1969) Purification and characterization of an antiH(O) phytohemagglutinin of Ulex europeus. Biochim. Bioplays. Acta 194,180-189 McCurry, K. R., Kooyman, D. L., Alvarado, C. G., Cotterel, A. H., Martin, M.
J., Logan, J. S., and Plaft, J. L. (1995) Human complement regulatory proteins protect swine-to primate cardiac xenografts from humoral injury. Nat. Med. 7, 423-427 Meri, et al., 1990. "Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers" Immunology 71:1-9.
Miller, A.D., Buttimore, C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Molecular and Cellular Biology 6:2895-2902, 1986.
Miyagawa, S., Shirakura, R., lwata, K., Nakata, S., Matsumiya, G., Izutani.
H., Matsuda, H., Terado, A., Matsumoto, M., Nagasawa, S., and Seya, T. (1994) Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAF hybrid, on complementmediated swine endothelial cell lysis. Transplantation 58, 834-840 Moran, et al., 1992. "Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo," J. Immunol. 149:1736-1743.
Morganstern, J.P., Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper free packaging cell line.
1990. Nucleic Acid Research. 18:3587.
Norris, et al., 1993. "Structure-Function Relationships of CD59," Blood, 82 (Suppl.):202a.
O'Hair, D. P., McManus, R. P., Komorowski, R. (1994) Inhibition of chronic rejection in primate cardiac xenografts using mycophenolate mofetil. Ann. Thorac. Surg. 58, Okada, et al., 1989. "Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement" J. Immunol. 143:2262-2266.
P. M. Wallace, J. S. Johnson, J. F. MacMaster, K. A. Kennedy, P. Gladstone. P.
S. Linsley.
1994. CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocomatibility complex barriers. Transpl. 58:602. (ms is better on ms than hu CTLA41 g) P. S. Linsley, W. Brady, M. Umes, L. S. Grosmaire, N. K. Dainle, J. A.
Ledbetter. 1991.
Pearson, T. C., D. Z. Alexander, K. J. Winn, P. S. Linsley, R. P. Lowry, C. P.
Larsen.
1994. Transplantation tolerance induced by CTLA4-1 a. Transpl. 57:1701.
Perkins et al., 1988. "A Study of the Structure of Human Complement Component Factor H
by Fourier Transform Infared Spectroscopy and Secondary Structure Averaging Methods,"
Biochemistry, 27:4004-4012.
Petranka, et al., 1993. "The Structure and Function of CD59: The Importance of the Disulfide Structure and Identification of a Primary Epitope," Molec. Immunol. 30 (suppl.
1):44.
Philbrick, et al., 1990. "The CD59 antigen is a structural homologue of murine Ly-6 antigens but lacks interferon inducibility" Eur. J. Immunol. 20:87-92.
Platt, J. L., and Bach, F. H. (1991) Discordant xenografting: challenges and controversies.
Curr. Opin. Immun. 3, 735-739 Pruitt, S. K., Kirk, A. D., Bollinger, R. R.. Marsh, H. C. Jr., Collins, B.
H., Levin, J. L., Mault, J. R., Heinle, J. S., Ibrahim, S., Rudolph, A. R., Baldwin 111, W. M., and Sanfilippo, F. (1994) The effect of soluble complement receptor type I on hyperacute rejection of porcine xenografts. Transplantation 57, 363-370 R. H. Schwartz. 1989. Clonal expansion vs. functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev.
Immunol. 7:445. (Signal two)**
R. H. Schwartz. 1~,~. C:ostimulation of T lymphocytes: The role o, ~D28. CTLA-4, and B7BB I in interleukin-2 production and immunotherapy. Cell 71:1065. (rev) Rollins, et al., 1990. "The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9" J. Immunol. 144:3478-3483.
Rollins, et al., 1991, "Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9" J. Immunol. 146:2345-2351.
Ross, S. C., and Densen, P. (1984) Complement deficiency states and infection:
epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency. Medicine 63, 243-273 Rother, et al.. 1994. "Inhibition of Complement-Mediated Cytolysis by the Terminal Complement Inhibitor of Herpesvirus Saimiri," J. Virol. 68:730-737.
S. A. Rollins, S. P. Kennedy, A. J. Chodera, E. A. Elliott. G. B. Zavoico, L.
A. Matis.
1994. Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2.
Transp1.57:1709.
S. E. Maher, K. KarTnann, W. Min, C. C. W. Hughes, J. S. Pober, A. L. M.
Bothwell.
1996. Porcine endothelial CD86 is a major costimulator of xenogeneic human T
cells. J.
Immunol. 157:3838.
Saadi, S., and Platt, J. L. ( 1995) Transient perturbations of endothelial integrity induced by natural antibodies and complement. J Exp. Med. 181. 21-31 Sambrook, J., Fritsch, E.F., and T. Maniatis. 1989. Molecular Cloning: A
laboratory manual.
2"a edition. Cold Spring Harbor Press.
Sandrin, M. S. (1997) Down-regulation of Galcc(1,3)Gal expression by alpha l,2fucosyltransferase. Further characterization of alpha I?-fucosyltransferase transgenic mice.
Transplantation 64, 495-500 Sandrin, M. S., Fodor, W. L., Mouhtouris. E., Osman, N., Cohney, S., Rollins, S. A., Guilmette, E. R., Setter, E., Squinto, S. P., and McKenzie, 1. F. C. ( 1995) Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med. l, 1261-1267 Sandrin. M. S., Vaughan, H. A.. Dabkowski. P. L., and McKenzie, 1. F. C. ( 1993) Anti-pig IgM antibodies in human serum reacts predominantly with Gal((XI,3)Gal epitopes. Proc. Natl.
Acad. Sci. USA 90,11391-11395 Sawada, et al., 1990. "Isolation and expression of the full-length cDNA
encoding CD59 antigen of human lymphocytes" DNA and Cell. Biol. 9: 213-220.
Schaapherder, A. F. M., Daha, M. R., Te Bulte, M. -T. J. W., Van der Woude, F.
J., and Gooszen, H. G. ( 1994) Antibody-dependant cell-mediated cytotoxicity against porcine endothelium induced by a majority of human sera. Transplantation 57, 1376-1382 Schwartz, "A Cell Culture Model for T Lymphocyte Clonal Anergy", Science 248:1349-1356 ( 1990).
Sharma, A., Okabe, J., Birch, P., McClellan, S. B., Martin, M. J., Platt. J.
L., and Logan, J.
S. (1996) Reduction in the level of Galcc(1,3)Gal in transgenic mice and pigs by expression of an (x(1,2)fucosyltransferase. Proc. NatL Acad. Sci. USA 93, 7190-7195 Sommerville, C. A., and D'Apice, A. J. F. (1993) Future directions in transplantation:
xenotransplantation. Kidney International 44, Suppl. 42, S I 12-S 121 Southern. E. M. ( 1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J MoL BioL 98, 503-517 Stefanova, et al., 1~a9. "Characterization of a broadly expressed hm.'an leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol" Mol.
Immunol. 26:153-161.
Storb and Thomas, "Graft-Versus-Host Disease in Dog and Man: The Seattle Experience", Immunol. Rev. 88:215-238 ( 1985).
Su, et al., 1991. "The Glycosyl Phosphatidylinositol Anchor Is Critical for Ly-6A/E-mediated T Cell Activation," J. Cell Biol. 112:377-384.
Sun, H. V. Subbotin, C. Chen, A. Aitouche, L. A. Valdivia, M. H. Sayegh, P. S.
Linsley, J.
J. Fung, T. E. Starzl, A. S. Rao. 1997. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody.
Transpl. 64:1838.
Thompson et al., "CD28 Activation Pathway Regulates the Production of Multiple T-Cell-Derived Lymphokines/Cytokines", Proc. Natl. Acad. Sci. 86:1333-1337 (1989).
Tone, et al., 1992. "Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation" J. Mol. Biol. 227:971-976.
Tran, H. M., P. W. Nicherson. A. C. Restifo, M. A. Ivis-Woodward, A. Patel, R.
D. Allen.
T. B. Strom, P. J. O'Connell. 1997. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-fc treatment. J. Immunol. 159:2232.
Vanhove, B., deMartin, R., Lipp, J., and Bach, F. H. (1994) Human xenoreactive natural antibodies of IgM isotype activate pig endothelial cells. Xenotransplantation l, 17-22 Venneker, et al., 1992. "CD59: a molecule involved in antigen presentation as well as downregulation of membrane attack complex" Exp. Clin. Immunogenet. 9:33-47.
W. L. Fodor, S. A. Rollins, E. R. Guilmette, E. Setter, S. P. Squinto. 1995. A
novel bifimctional chimeric complement inhibitor that regulates C3 convertase and fon-nation of the membrane attack complex. J. Immunol 155:4135.
W. Steurer, P. W. Nickerson, S. W. Steele, J. Steiger. X. X. Zheng T. B. Strom 1995. Ex vivo coating of Islet cell allografts with murine CTLA4/fc promotes graft tolerance. J.
Immunol. 155:1165.
Walsh, et al., 1991. "Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement" Eur. J. Immunol. 21:847-850.
Walunas, T. L., D. J. Lenschow, C. Y. Bakker. P. S. Linsley, G. J. Freeman. J.
M. Green.
C. B. Thompson, J. A. Bluestone. 1994. CTLA-4 can ftinction as a negative regulator of T
cell activation. Immunity 1:405.
Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian. K. P.
Lee, C. B.
Thompson, H. Griesser, T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Sci 270:985.
Weaver and Unanue, "The Costimulatory Function of Antigen-Presenting Cells", Immunol.
Today 11:49-55 ( 1990).
Weiss, "Structure and Function of the T Cell Antigen Receptor", J. Clin.
Invest. 86:1015-1022 ( 1990).
Whitlow, et al., 1990. "H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement" Cell. Immunol. 126:176-184.
Wing, et al., 1992. "Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59"
Immunology 76:140-145.
Wm. Paul. 1998. Fundamental Immunology. Fourth Edition WO01/30966 ~ 02361646 2001-07-30 pCT~S00/29151 Yokochi et al., "B L~mpnoblast Antigen (BB-1) Expressed on Epstv__'-Barr Virus-Activated B
Cells Blasts, B Lymphoblastoid Cell Lines, and Burkitt's Lv_ mphomas", J.
Immunol.
128:823:827 (1981).
Zhao, et al., 1991. "Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement"J. Bioi.
Chem. 266: 13418-13422.
It will be understood that various modifications may be made to the embodiments disclosed herein. For example, the CSb-9 inhibitory domain and/or the T Cell inhibitory domain may be modified by creating amino acid substitutions or nucleic acid mutations provided at least some complement regulatory activity and some T Cell inhibitory activity remains after such modifications. Similarly, the nucleotide sequences of the chimeric protein protein may be modified by creating nucleic acid mutations which do not significantly change the encoded amino acid sequences, including third nucleotide changes in degenerate codons (and other "silent"
mutations that do not change the encoded amino acid sequence). Mutations which result in a highly conservative or silent amino acid substitution for an encoded amino acid while leaving the characteristics of the chimeric proteins essentially unchanged are also within the scope of disclosure. Also included are sequences comprising changes that are found as naturally occurring allelic variants of the genes for the T Cell inhibitory molecules and the CSb-9 inhibitory molecules used to create chimeric molecules described herein. All of the foregoing shall be considered as equivalents of the specific embodiments set forth herein. Therefore, the above description should not be construed as limiting, but merely as exemplifications of preferred embodiments. Those skilled in the an will envision other modifications within the scope of the claims appended hereto.
Claims (22)
1. A chimeric protein capable of inhibiting both cellular and humoral immune responses.
2. A chimeric protein comprising a domain having C5b-9 inhibitory activity and a domain having T Cell inhibitory activity.
3. A chimeric protein according to claim 2, wherein the protein exhibits at least about 25% of the C5b-9 inhibitory activity activity of said naturally occurring C5b-9 inhibitor protein.
4. A chimeric protein according to claim 2, wherein the protein has at least about 25% of the T
Cell inhibitory activity of a naturally occurring T Cell inhibitor protein.
Cell inhibitory activity of a naturally occurring T Cell inhibitor protein.
5. A chimeric protein according to claim 2, wherein the domain having C5b-9 inhibitory activity is derived from mammalian CD59.
6. A chimeric protein according to claim 2, wherein the domain having T Cell inhibitory activity is derived from mammalian CTLA4.
7. A chimeric protein according to claim 6, wherein the mammalian CTLA4 is selected from the group consisting of human and porcine CTLA4.
8. A chimeric protein according to claim 2, wherein the protein includes a linker region between the domain having C5b-9 inhibitory activity and the domain having T
Cell inhibitory activity.
Cell inhibitory activity.
9. A chimeric protein according to claim 2, further comprising a cellular anchor moiety.
10. A chimeric protein according to claim 9, wherein the cellular anchor moiety is a GPI
anchor.
anchor.
11. A chimeric DNA construct comprising a domain derived from a DNA sequence encoding a a domain having C5b-9 inhibitory activity and a DNA sequence encoding a domain having T Cell inhibitory activity.
12. A chimeric DNA construct according to claim 11, wherein the DNA sequence encoding a domain having C5b-9 inhibitory activity is derived from a DNA sequence encoding CD59.
13. A chimeric DNA construct according to claim 11, wherein the DNA sequence encoding a domain having T Cell inhibitory activity is derived from a DNA sequence encoding mammalian CTLA4.
14. A chimeric DNA construct according to claim 11, wherein the the mammalian CTLA4 is selected from the group consisting of human and porcine CTLA4.
15. A cloning vector comprising a DNA construct according to claim 11.
16. A cloning vector according to claim 15, wherein the cloning vector is a retroviral vector.
17. A host cell transformed by the vector of claim 15.
18. Transgenic porcine cells comprising the chimeric protein of claim 10.
19. Transgenic porcine tissues comprising the chimeric protein of claim 10.
20. Transgenic whole organs comprising the chimeric protein of claim 10.
21. A chimeric protein comprising a domain having C3 inhibitory activity and a domain having T Cell inhibitory activity.
22. A chimeric protein according to claim 21, wherein the domain having C5b-9 inhibitory activity is derived from mammalian DAF.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16118699P | 1999-10-22 | 1999-10-22 | |
US60/161,186 | 1999-10-22 | ||
PCT/US2000/029151 WO2001030966A2 (en) | 1999-10-22 | 2000-10-21 | An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2361646A1 true CA2361646A1 (en) | 2001-05-03 |
Family
ID=22580195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002361646A Abandoned CA2361646A1 (en) | 1999-10-22 | 2000-10-21 | An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1165752A4 (en) |
AU (1) | AU1340101A (en) |
CA (1) | CA2361646A1 (en) |
WO (1) | WO2001030966A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ565711A (en) | 2005-08-09 | 2011-10-28 | Revivicor Inc | Transgenic ungulates expressing a porcine CTLA4 peptide fused to an immunoglobulin |
KR20180036810A (en) | 2009-08-14 | 2018-04-09 | 레비비코르 인코포레이션 | Multi-transgenic pigs for diabetes treatment |
KR20130049775A (en) | 2010-03-12 | 2013-05-14 | 애브비 바이오테라퓨틱스 인크. | Ctla4 proteins and their uses |
ES2680636T3 (en) | 2011-02-14 | 2018-09-10 | Revivicor Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
CA3196707A1 (en) | 2020-11-20 | 2022-05-27 | Martine Rothblatt | Multi-transgenic pigs with growth hormone receptor knockout for xenotransplantation |
IL311538A (en) | 2021-09-20 | 2024-05-01 | Revivicor Inc | Multitransgenic pigs comprising ten genetic modifications for xenotransplantation |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US6090914A (en) * | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5627264A (en) * | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
-
2000
- 2000-10-21 WO PCT/US2000/029151 patent/WO2001030966A2/en not_active Application Discontinuation
- 2000-10-21 AU AU13401/01A patent/AU1340101A/en not_active Abandoned
- 2000-10-21 CA CA002361646A patent/CA2361646A1/en not_active Abandoned
- 2000-10-21 EP EP00975335A patent/EP1165752A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1165752A4 (en) | 2003-02-05 |
WO2001030966A3 (en) | 2001-10-18 |
WO2001030966A2 (en) | 2001-05-03 |
EP1165752A2 (en) | 2002-01-02 |
AU1340101A (en) | 2001-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0750458B1 (en) | Terminal complement inhibitor fusion genes and proteins | |
EP0754227B1 (en) | Chimeric complement inhibitor proteins | |
EP0833906B1 (en) | Novel ctla4/cd28 ligands and uses therefor | |
US9090708B2 (en) | Porcine CTLA-4 for xenograft-specific immunosuppression | |
EP0711345A1 (en) | B7-2: ctl a4/cd 28 counter receptor | |
JP4236925B2 (en) | Novel polypeptides involved in immune responses | |
CA2361646A1 (en) | An engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system | |
US20030157705A1 (en) | Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system | |
US6824779B1 (en) | Methods for inhibiting the interaction of B7-2 with its natural ligand | |
US20030086940A1 (en) | Engineered recombinant molecule that regulates humoral and cellular effector functions of the immune system | |
AU5339500A (en) | Novel CTLA4/CD28 ligands and uses therefor | |
Smith | Expression, function and ligands for the Ly-49H NK cell activation receptor | |
Jamieson | The role of the stimulatory immunoreceptor NKG2D in the immune response to tumors and infectious disease | |
NZ535708A (en) | Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20061023 |